0001630113 2022-04-01 2022-12-31 0001630113 2023-02-14 0001630113 2022-12-31 0001630113 2022-03-31 0001630113 us-gaap:SeriesAPreferredStockMember 2022-12-31 0001630113 us-gaap:SeriesAPreferredStockMember 2022-03-31 0001630113 2022-10-01 2022-12-31 0001630113 2021-10-01 2021-12-31 0001630113 2021-04-01 2021-12-31 0001630113 us-gaap:PreferredStockMember 2022-09-30 0001630113 us-gaap:CommonStockMember 2022-09-30 0001630113 BTCY:SharesToBeIssuedMember 2022-09-30 0001630113 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001630113 us-gaap:RetainedEarningsMember 2022-09-30 0001630113 2022-09-30 0001630113 us-gaap:PreferredStockMember 2022-10-01 2022-12-31 0001630113 us-gaap:CommonStockMember 2022-10-01 2022-12-31 0001630113 BTCY:SharesToBeIssuedMember 2022-10-01 2022-12-31 0001630113 us-gaap:AdditionalPaidInCapitalMember 2022-10-01 2022-12-31 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-10-01 2022-12-31 0001630113 us-gaap:RetainedEarningsMember 2022-10-01 2022-12-31 0001630113 us-gaap:PreferredStockMember 2022-12-31 0001630113 us-gaap:CommonStockMember 2022-12-31 0001630113 BTCY:SharesToBeIssuedMember 2022-12-31 0001630113 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001630113 us-gaap:RetainedEarningsMember 2022-12-31 0001630113 us-gaap:PreferredStockMember 2022-03-31 0001630113 us-gaap:CommonStockMember 2022-03-31 0001630113 BTCY:SharesToBeIssuedMember 2022-03-31 0001630113 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001630113 us-gaap:RetainedEarningsMember 2022-03-31 0001630113 us-gaap:PreferredStockMember 2022-04-01 2022-12-31 0001630113 us-gaap:CommonStockMember 2022-04-01 2022-12-31 0001630113 BTCY:SharesToBeIssuedMember 2022-04-01 2022-12-31 0001630113 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-12-31 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-12-31 0001630113 us-gaap:RetainedEarningsMember 2022-04-01 2022-12-31 0001630113 us-gaap:PreferredStockMember 2021-09-30 0001630113 us-gaap:CommonStockMember 2021-09-30 0001630113 BTCY:SharesToBeIssuedMember 2021-09-30 0001630113 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0001630113 us-gaap:RetainedEarningsMember 2021-09-30 0001630113 2021-09-30 0001630113 us-gaap:PreferredStockMember 2021-10-01 2021-12-31 0001630113 us-gaap:CommonStockMember 2021-10-01 2021-12-31 0001630113 BTCY:SharesToBeIssuedMember 2021-10-01 2021-12-31 0001630113 us-gaap:AdditionalPaidInCapitalMember 2021-10-01 2021-12-31 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-10-01 2021-12-31 0001630113 us-gaap:RetainedEarningsMember 2021-10-01 2021-12-31 0001630113 us-gaap:PreferredStockMember 2021-12-31 0001630113 us-gaap:CommonStockMember 2021-12-31 0001630113 BTCY:SharesToBeIssuedMember 2021-12-31 0001630113 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001630113 us-gaap:RetainedEarningsMember 2021-12-31 0001630113 2021-12-31 0001630113 us-gaap:PreferredStockMember 2021-03-31 0001630113 us-gaap:CommonStockMember 2021-03-31 0001630113 BTCY:SharesToBeIssuedMember 2021-03-31 0001630113 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001630113 us-gaap:RetainedEarningsMember 2021-03-31 0001630113 2021-03-31 0001630113 us-gaap:PreferredStockMember 2021-04-01 2021-12-31 0001630113 us-gaap:CommonStockMember 2021-04-01 2021-12-31 0001630113 BTCY:SharesToBeIssuedMember 2021-04-01 2021-12-31 0001630113 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-12-31 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-12-31 0001630113 us-gaap:RetainedEarningsMember 2021-04-01 2021-12-31 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2021-04-01 2021-06-30 0001630113 2021-04-01 2021-09-30 0001630113 BTCY:TechnologyFeesSalesMember 2022-10-01 2022-12-31 0001630113 BTCY:TechnologyFeesSalesMember 2021-10-01 2021-12-31 0001630113 BTCY:TechnologyFeesSalesMember 2022-04-01 2022-12-31 0001630113 BTCY:TechnologyFeesSalesMember 2021-04-01 2021-12-31 0001630113 BTCY:DeviceSalesMember 2022-10-01 2022-12-31 0001630113 BTCY:DeviceSalesMember 2021-10-01 2021-12-31 0001630113 BTCY:DeviceSalesMember 2022-04-01 2022-12-31 0001630113 BTCY:DeviceSalesMember 2021-04-01 2021-12-31 0001630113 BTCY:ServiceRelatedAndOtherRevenueMember 2022-10-01 2022-12-31 0001630113 BTCY:ServiceRelatedAndOtherRevenueMember 2021-10-01 2021-12-31 0001630113 BTCY:ServiceRelatedAndOtherRevenueMember 2022-04-01 2022-12-31 0001630113 BTCY:ServiceRelatedAndOtherRevenueMember 2021-04-01 2021-12-31 0001630113 us-gaap:OfficeEquipmentMember 2022-04-01 2022-12-31 0001630113 us-gaap:LeaseholdImprovementsMember 2022-04-01 2022-12-31 0001630113 BTCY:SeriesANotesMember 2020-04-01 2021-03-31 0001630113 BTCY:SeriesANotesMember 2022-03-31 0001630113 BTCY:SeriesANotesMember 2022-04-01 2022-12-31 0001630113 BTCY:SeriesANotesSecondMember 2022-12-31 0001630113 BTCY:SeriesANotesSecondMember 2022-04-01 2022-12-31 0001630113 BTCY:SeriesANotesMember us-gaap:WarrantMember 2021-04-01 2022-03-31 0001630113 BTCY:PlacementAgentMember BTCY:SeriesANotesMember 2021-04-01 2022-03-31 0001630113 BTCY:PlacementAgentMember us-gaap:WarrantMember 2021-04-01 2022-03-31 0001630113 2021-01-08 0001630113 BTCY:SeriesANotesMember 2022-12-31 0001630113 BTCY:SeriesANoteMember 2022-12-30 0001630113 BTCY:NewConvertibleNoteMember 2022-12-30 0001630113 BTCY:NewConvertibleNoteMember 2022-12-29 2022-12-30 0001630113 BTCY:SeriesANoteMember 2022-12-31 0001630113 BTCY:SeriesBNotesMember BTCY:AccreditedInvestorsMember 2021-03-31 0001630113 BTCY:ConversionNoticeMember 2022-04-01 2022-12-31 0001630113 BTCY:SeriesBNotesMember 2022-04-01 2022-12-31 0001630113 BTCY:SeriesBNotesMember us-gaap:WarrantMember 2022-12-31 0001630113 BTCY:SeriesBNotesMember us-gaap:WarrantMember 2022-03-31 0001630113 BTCY:SeriesBNotesMember 2020-04-01 2021-03-31 0001630113 BTCY:SeriesBNotesMember 2022-03-31 0001630113 BTCY:SeriesBNotesMember 2022-10-01 2022-12-31 0001630113 BTCY:SeriesBNotesMember 2022-12-31 0001630113 us-gaap:SeriesBPreferredStockMember 2022-12-31 0001630113 BTCY:ShortTermSecuritizedBridgeLoanMember BTCY:CFGMerchantSolutionsLLCMember 2022-12-08 2022-12-08 0001630113 BTCY:ShortTermSecuritizedBridgeLoanMember BTCY:CFGMerchantSolutionsLLCMember 2022-12-08 0001630113 BTCY:ShortTermSecuritizedBridgeLoanMember BTCY:CFGMerchantSolutionsLLCMember 2022-12-14 2022-12-16 0001630113 BTCY:ShortTermSecuritizedBridgeLoanMember BTCY:CFGMerchantSolutionsLLCMember 2022-12-16 0001630113 BTCY:ShortTermSecuritizedBridgeLoanMember BTCY:CFGMerchantSolutionsLLCMember 2022-12-31 0001630113 BTCY:RepayWithInThirtyDaysMember 2022-04-01 2022-12-31 0001630113 BTCY:RepayWithInSixtyDaysMember 2022-04-01 2022-12-31 0001630113 BTCY:RepayWithInNinetyDaysMember 2022-04-01 2022-12-31 0001630113 BTCY:ShortTermSecuritizedBridgeLoanMember BTCY:BalancedManagementLLCMember 2022-12-21 2022-12-21 0001630113 BTCY:ShortTermSecuritizedBridgeLoanMember BTCY:BalancedManagementLLCMember 2022-12-21 0001630113 BTCY:ShortTermSecuritizedBridgeLoanMember BTCY:BalancedManagementLLCMember 2022-12-30 2022-12-30 0001630113 BTCY:FirstFourWeeksMember BTCY:ShortTermSecuritizedBridgeLoanMember BTCY:BalancedManagementLLCMember 2022-12-30 2022-12-30 0001630113 BTCY:ShortTermSecuritizedBridgeLoanMember BTCY:CFGMerchantSolutionsLLCMember 2022-12-30 0001630113 BTCY:ShortTermSecuritizedBridgeLoanMember BTCY:BalancedManagementAgreementMember BTCY:CFGMerchantSolutionsLLCMember 2022-12-31 0001630113 BTCY:RepayWithInThirtyDaysMember 2022-12-31 0001630113 BTCY:RepayWithInSixtyDaysMember 2022-12-31 0001630113 BTCY:RepayWithInNinetyDaysMember 2022-12-31 0001630113 BTCY:RepayWithInOneTwentyDaysMember 2022-12-31 0001630113 BTCY:RepayWithInOneFiftyDaysMember 2022-12-31 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorMember 2022-12-15 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorMember 2022-12-14 2022-12-15 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorMember 2022-12-31 0001630113 2022-12-30 2022-12-30 0001630113 BTCY:PromissoryNoteMember 2022-12-30 0001630113 2021-12-21 0001630113 2021-12-19 2021-12-21 0001630113 2021-12-21 2021-12-21 0001630113 us-gaap:CashMember 2021-12-21 0001630113 2022-12-19 2022-12-21 0001630113 BTCY:TermLoanMember 2022-10-01 2022-12-31 0001630113 BTCY:TermLoanMember 2022-04-01 2022-12-31 0001630113 BTCY:TermLoanOneMember 2022-10-01 2022-12-31 0001630113 BTCY:TermLoanOneMember 2022-04-01 2022-12-31 0001630113 2022-12-21 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2020-04-01 2020-04-30 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2020-04-30 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2021-05-01 2021-05-31 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2022-10-01 2022-12-31 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2022-04-01 2022-12-31 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2021-10-01 2021-12-31 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2021-04-01 2021-12-31 0001630113 BTCY:PaycheckProtectionProgramMember 2020-05-01 2020-05-31 0001630113 BTCY:PaycheckProtectionProgramMember 2020-04-01 2021-03-31 0001630113 us-gaap:SeriesAPreferredStockMember 2020-01-09 0001630113 us-gaap:SeriesAPreferredStockMember 2020-01-08 2020-01-09 0001630113 BTCY:PromissoryNotesMember 2019-10-01 2019-10-31 0001630113 us-gaap:SeriesAPreferredStockMember 2020-05-22 0001630113 us-gaap:SeriesAPreferredStockMember 2020-05-20 2020-05-22 0001630113 us-gaap:SeriesAPreferredStockMember 2021-07-01 2021-09-30 0001630113 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2021-10-01 2021-12-31 0001630113 us-gaap:PreferredStockMember 2022-04-01 2022-06-30 0001630113 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2022-04-01 2022-06-30 0001630113 us-gaap:PreferredStockMember 2022-07-01 2022-09-30 0001630113 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2022-07-01 2022-09-30 0001630113 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2022-10-01 2022-12-31 0001630113 us-gaap:ConvertibleDebtMember 2022-04-01 2022-12-31 0001630113 2022-04-01 2022-06-30 0001630113 2021-04-01 2021-06-30 0001630113 2022-06-30 0001630113 2021-06-30 0001630113 2022-07-01 2022-09-30 0001630113 2021-07-01 2021-09-30 0001630113 us-gaap:ConvertibleDebtMember 2022-03-31 0001630113 us-gaap:ConvertibleDebtMember 2021-03-31 0001630113 us-gaap:ConvertibleDebtMember 2022-04-01 2022-06-30 0001630113 us-gaap:ConvertibleDebtMember 2021-04-01 2021-06-30 0001630113 us-gaap:ConvertibleDebtMember 2022-06-30 0001630113 us-gaap:ConvertibleDebtMember 2021-06-30 0001630113 us-gaap:ConvertibleDebtMember 2022-07-01 2022-09-30 0001630113 us-gaap:ConvertibleDebtMember 2021-07-01 2021-09-30 0001630113 us-gaap:ConvertibleDebtMember 2022-09-30 0001630113 us-gaap:ConvertibleDebtMember 2021-09-30 0001630113 us-gaap:ConvertibleDebtMember 2022-10-01 2022-12-31 0001630113 us-gaap:ConvertibleDebtMember 2021-10-01 2021-12-31 0001630113 us-gaap:ConvertibleDebtMember 2022-12-31 0001630113 us-gaap:ConvertibleDebtMember 2021-12-31 0001630113 us-gaap:MeasurementInputExpectedDividendRateMember 2022-12-31 0001630113 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-12-31 0001630113 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-12-31 0001630113 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0001630113 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0001630113 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember 2022-04-01 2022-12-31 0001630113 srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember 2022-04-01 2022-12-31 0001630113 srt:MinimumMember 2022-12-31 0001630113 srt:MaximumMember 2022-12-31 0001630113 srt:MinimumMember BTCY:ConversionAndRedemptionFeaturesMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-12-31 0001630113 srt:MaximumMember BTCY:ConversionAndRedemptionFeaturesMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-12-31 0001630113 srt:MinimumMember BTCY:ConversionAndRedemptionFeaturesMember us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0001630113 srt:MaximumMember BTCY:ConversionAndRedemptionFeaturesMember us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0001630113 srt:MinimumMember BTCY:ConversionAndRedemptionFeaturesMember us-gaap:MeasurementInputExpectedTermMember 2022-04-01 2022-12-31 0001630113 srt:MaximumMember BTCY:ConversionAndRedemptionFeaturesMember us-gaap:MeasurementInputExpectedTermMember 2022-04-01 2022-12-31 0001630113 srt:MinimumMember BTCY:ConversionAndRedemptionFeaturesMember 2022-12-31 0001630113 srt:MaximumMember BTCY:ConversionAndRedemptionFeaturesMember 2022-12-31 0001630113 BTCY:ShareholdersMember BTCY:ExchangeAgreementMember 2022-04-01 2022-12-31 0001630113 BTCY:ShareholdersMember BTCY:ExchangeAgreementMember 2021-04-01 2022-03-31 0001630113 BTCY:ShareholdersMember BTCY:ExchangeAgreementMember 2016-02-01 2016-02-02 0001630113 BTCY:ExchangeAgreementMember 2016-02-01 2016-02-02 0001630113 BTCY:ExchangecoMember BTCY:ExchangeAgreementMember 2016-02-01 2016-02-02 0001630113 BTCY:OptionsMember BTCY:ExchangeAgreementMember 2016-02-01 2016-02-02 0001630113 us-gaap:WarrantMember BTCY:ExchangeAgreementMember 2016-02-01 2016-02-02 0001630113 BTCY:AdvisorWarrantMember BTCY:ExchangeAgreementMember 2016-02-01 2016-02-02 0001630113 BTCY:ElevenPercentageSecuredConvertiblePromissoryNotesMember BTCY:ExchangeAgreementMember 2016-02-01 2016-02-02 0001630113 us-gaap:SeriesAPreferredStockMember 2022-04-01 2022-12-31 0001630113 BTCY:ConvertiblePromissoryNotesMember 2021-04-01 2022-03-31 0001630113 BTCY:ConvertiblePromissoryNotesMember 2022-03-31 0001630113 us-gaap:WarrantMember 2021-04-01 2022-03-31 0001630113 BTCY:CashlessWarrantMember 2021-04-01 2022-03-31 0001630113 2021-04-01 2022-03-31 0001630113 BTCY:SharesToBeIssuedMember 2021-04-01 2022-03-31 0001630113 BTCY:UplistingPublicStockOfferingMember 2021-04-01 2022-03-31 0001630113 us-gaap:SeriesAPreferredStockMember 2021-04-01 2022-03-31 0001630113 BTCY:InvestorsMember 2021-04-01 2022-03-31 0001630113 BTCY:ConvertiblePromissoryNotesMember 2022-04-01 2022-06-30 0001630113 BTCY:ConvertiblePromissoryNotesMember 2022-06-30 0001630113 BTCY:IssuanceOfCommonSharesMember 2022-04-01 2022-06-30 0001630113 us-gaap:WarrantMember 2022-04-01 2022-06-30 0001630113 srt:MinimumMember BTCY:IssuanceOfCommonSharesMember 2022-04-01 2022-06-30 0001630113 BTCY:ConvertiblePromissoryNotesMember 2022-07-01 2022-09-30 0001630113 BTCY:ConvertiblePromissoryNotesMember 2022-09-30 0001630113 BTCY:ConvertiblePromissoryNotesMember 2022-10-01 2022-12-31 0001630113 BTCY:ConvertiblePromissoryNotesMember 2022-12-31 0001630113 us-gaap:WarrantMember 2022-03-31 0001630113 BTCY:AdvisorAndConsultantMember us-gaap:WarrantMember 2021-04-01 2022-03-31 0001630113 BTCY:AdvisorAndConsultantMember 2021-04-01 2022-03-31 0001630113 srt:ExecutiveOfficerMember us-gaap:WarrantMember 2021-04-01 2022-03-31 0001630113 us-gaap:GeneralAndAdministrativeExpenseMember 2021-04-01 2022-03-31 0001630113 BTCY:LendersMember us-gaap:WarrantMember 2022-03-31 0001630113 BTCY:LendersMember us-gaap:WarrantMember 2021-04-01 2022-03-31 0001630113 BTCY:UnderwriterMember us-gaap:WarrantMember 2022-03-31 0001630113 BTCY:UnderwriterMember us-gaap:WarrantMember 2021-04-01 2022-03-31 0001630113 BTCY:ExecutiveMember us-gaap:WarrantMember 2022-04-01 2022-06-30 0001630113 us-gaap:GeneralAndAdministrativeExpenseMember 2022-06-30 0001630113 BTCY:ExecutiveMember us-gaap:WarrantMember 2022-07-01 2022-09-30 0001630113 us-gaap:GeneralAndAdministrativeExpenseMember 2022-09-30 0001630113 BTCY:ExecutiveMember us-gaap:WarrantMember 2022-10-01 2022-12-31 0001630113 us-gaap:GeneralAndAdministrativeExpenseMember 2022-12-31 0001630113 us-gaap:WarrantMember 2022-04-01 2022-12-31 0001630113 us-gaap:WarrantMember 2022-12-31 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2016-02-02 0001630113 BTCY:EmployeeMember BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2022-04-01 2022-12-31 0001630113 BTCY:EmployeeMember BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2019-04-01 2020-03-31 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2019-04-01 2020-03-31 0001630113 BTCY:BoardOfDirectorMember BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2019-04-01 2020-03-31 0001630113 srt:MinimumMember BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2019-04-01 2020-03-31 0001630113 srt:MaximumMember BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2019-04-01 2020-03-31 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2020-03-31 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2022-04-01 2022-06-30 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2021-04-01 2021-06-30 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2022-07-01 2022-09-30 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2021-07-01 2021-09-30 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2022-10-01 2022-12-31 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2021-10-01 2021-12-31 0001630113 BTCY:BrokerAndOtherWarrantsMember 2022-03-31 0001630113 BTCY:ConsultantWarrantsMember 2022-03-31 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNotesMember 2022-03-31 0001630113 BTCY:BrokerAndOtherWarrantsMember 2022-04-01 2022-06-30 0001630113 BTCY:ConsultantWarrantsMember 2022-04-01 2022-06-30 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNotesMember 2022-04-01 2022-06-30 0001630113 BTCY:BrokerAndOtherWarrantsMember 2022-06-30 0001630113 BTCY:ConsultantWarrantsMember 2022-06-30 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNotesMember 2022-06-30 0001630113 BTCY:BrokerAndOtherWarrantsMember 2022-07-01 2022-09-30 0001630113 BTCY:ConsultantWarrantsMember 2022-07-01 2022-09-30 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNotesMember 2022-07-01 2022-09-30 0001630113 BTCY:BrokerAndOtherWarrantsMember 2022-09-30 0001630113 BTCY:ConsultantWarrantsMember 2022-09-30 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNotesMember 2022-09-30 0001630113 BTCY:BrokerAndOtherWarrantsMember 2022-10-01 2022-12-31 0001630113 BTCY:ConsultantWarrantsMember 2022-10-01 2022-12-31 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNotesMember 2022-10-01 2022-12-31 0001630113 BTCY:BrokerAndOtherWarrantsMember 2022-12-31 0001630113 BTCY:ConsultantWarrantsMember 2022-12-31 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNotesMember 2022-12-31 0001630113 srt:MinimumMember BTCY:BrokerWarrantsMember 2022-12-31 0001630113 srt:MaximumMember BTCY:BrokerWarrantsMember 2022-12-31 0001630113 srt:MinimumMember BTCY:ConsultantWarrantsMember 2022-12-31 0001630113 srt:MaximumMember BTCY:ConsultantWarrantsMember 2022-12-31 0001630113 srt:MinimumMember BTCY:WarrantsIssuedOnConversionOfConvertibleNoteMember 2022-12-31 0001630113 srt:MaximumMember BTCY:WarrantsIssuedOnConversionOfConvertibleNoteMember 2022-12-31 0001630113 BTCY:BrokerWarrantsMember 2022-04-01 2022-12-31 0001630113 BTCY:ConsultantWarrantsMember 2022-04-01 2022-12-31 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNotesMember 2022-04-01 2022-12-31 0001630113 us-gaap:StockOptionMember 2022-03-31 0001630113 us-gaap:StockOptionMember 2022-04-01 2022-06-30 0001630113 us-gaap:StockOptionMember 2022-06-30 0001630113 us-gaap:StockOptionMember 2022-07-01 2022-09-30 0001630113 us-gaap:StockOptionMember 2022-09-30 0001630113 us-gaap:StockOptionMember 2022-10-01 2022-12-31 0001630113 us-gaap:StockOptionMember 2022-12-31 0001630113 srt:MinimumMember srt:ScenarioForecastMember 2023-03-31 0001630113 srt:MaximumMember srt:ScenarioForecastMember 2023-03-31 0001630113 srt:MinimumMember 2022-03-31 0001630113 srt:MaximumMember 2022-03-31 0001630113 srt:MinimumMember srt:ScenarioForecastMember 2022-04-01 2023-03-31 0001630113 srt:MaximumMember srt:ScenarioForecastMember 2022-04-01 2023-03-31 0001630113 srt:MinimumMember 2021-04-01 2022-03-31 0001630113 srt:MaximumMember 2021-04-01 2022-03-31 0001630113 srt:ScenarioForecastMember 2022-04-01 2023-03-31 0001630113 BTCY:NewLeaseAgreementMember 2021-12-01 0001630113 us-gaap:GeneralAndAdministrativeExpenseMember 2022-10-01 2022-12-31 0001630113 us-gaap:GeneralAndAdministrativeExpenseMember 2022-04-01 2022-12-31 0001630113 us-gaap:GeneralAndAdministrativeExpenseMember 2021-10-01 2021-12-31 0001630113 us-gaap:GeneralAndAdministrativeExpenseMember 2021-04-01 2021-12-31 0001630113 us-gaap:LeaseholdImprovementsMember 2021-04-01 2022-03-31 0001630113 us-gaap:FurnitureAndFixturesMember 2021-04-01 2022-03-31 0001630113 us-gaap:OfficeEquipmentMember 2022-03-31 0001630113 us-gaap:LeaseholdImprovementsMember 2022-03-31 0001630113 us-gaap:OfficeEquipmentMember 2022-12-31 0001630113 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001630113 us-gaap:OfficeEquipmentMember 2022-04-01 2022-06-30 0001630113 us-gaap:LeaseholdImprovementsMember 2022-04-01 2022-06-30 0001630113 us-gaap:OfficeEquipmentMember 2022-07-01 2022-09-30 0001630113 us-gaap:LeaseholdImprovementsMember 2022-07-01 2022-09-30 0001630113 us-gaap:OfficeEquipmentMember 2022-10-01 2022-12-31 0001630113 us-gaap:LeaseholdImprovementsMember 2022-10-01 2022-12-31 0001630113 BTCY:NewConvertibleNoteMember us-gaap:SubsequentEventMember 2023-01-31 0001630113 BTCY:NewConvertibleNoteMember us-gaap:SubsequentEventMember 2023-01-31 2023-01-31 0001630113 BTCY:DebtConvertibleNoteHolderMember us-gaap:SubsequentEventMember 2023-01-01 2023-01-31 0001630113 us-gaap:SubsequentEventMember 2023-01-01 2023-01-31 iso4217:USD shares iso4217:USD shares pure 0001630113 false Q3 --03-31 2023

10-Q true 2022-12-31 false 000-56074 BIOTRICITY INC. NV 30-0983531 203 Redwood Shores Parkway Suite 600 Redwood City CA 94065 (650) 832-1626 Yes Yes Non-accelerated Filer true false false Common Stock, par value $0.001 per share BTCY NASDAQ 51047864

451421

12066929

1975403

2006678

1931894

842924

435657

406280

4794375

15322811

85000

72074

22994

27459

1672653

1242700

6647096

16677970

3490426

2595747

3125637

1540000

351719

520747

322882

210320

7290664

4866814

870800

11764642

11612672

741675

352402

1461022

1120018

22128803

18822706

0.001

10000000

0.001

20000

6305

7201

0.001

125000000

50775354

49810322

1466718

52242

51277

23723 123817 24999 102299

92297390

91507478

-142958

-768656

-107713387

-93037142

-15481707

-2144736

6647096

16677970

2459181

1930108

6896622

5501527

1057215

1105271

2989290

2372011

1401966

824837

3907332

3129516

4777366

4659638

14542230

13921024

876460

900499

2526550

2115134

5653826

5560137

17068780

16036158

-4251860

-4735300

-13161448

-12906642

-119880

40512

-116989

54558

5391

-305246

-85537

-1155643

-51061

-1334842

-151970

-8834728

-99705

-774773

-469971

-676182

-4517115

-7109649

-13985915

-23518637

-4517115

-7109649

-13985915

-23518637

230374

233222

690330

719086

-4747489

-7342871

-14676245

-24237723

-72823

-20064

625698

-1841

-4820312

-7362935

-14050547

-24239564

-0.091

-0.149

-0.283

-0.554

52142669

49168264

51814972

43747569

6802

51897963

51898

23723

24999

92335492

-70135

-102965898

-10623636

238846

239

211363

211602

-497 -1 -431128 -431129

105263

105

112526

112631

77780

-71768 -71768

63125

-72823

-4517115

230374 230374

6305

52242072

52242

23723

24999

92297390

-142958

-107713387

-15481707

7201

51277040

51277

123817

102299

91507478

-768656

-93037142

-2144736

761038

761

843161

843922

-896 -1 -777174 -777175

132202

132

150286

150418

71792 72 -100094 -77300 47228 -30000 232526 232526 -71768 -71768

365653

625698

-13985915

690330 690330

6305

52242072

52242

23723

24999

92297390

-142958

-107713387

-15481707

8146

48876312

48876

1014303

3130926

84893876

-615963

-79712541

7745183

207516

208

875105

875313

37820 38 153133 153171

-715

-1

288756

1198914

-715000

483913

-230 -230000 -230000

131522

132

-81522

-255979

398348

142501

42500 43 11792 12500 26608 39151 371763 371763

100650

361190 361 361

-20064

-7109649

233222 233222

7201

49656860

49657

1233329

4086361

85874483

-636027

-87055411

2319071

8046

39014942

39015

268402

280960

56298726

-634186

-62817688

-6833164

8046

39014942

39015

268402

280960

56298726

-634186

-62817688

-6833164

69252

249931

250000

100 100000 100000 37820 38 153133 153171 5382331 5382 14540423 14545805

4056204

4056

602059

2528987

12992240

15525283

-715

-1

288756

1198914

-715000

483913

-230 -230000 -230000

313188

313

966779

967092

336753 337 73112 77500 441127 518964 668013 668013

-17084

426280

446370 446 1000 -85 361

-1841

-23518637

719086 719086

7201

49656860

49657

1233329

4086361

85874483

-636027

-87055411

2319071

7201

49656860

49657

1233329

4086361

85874483

-636027

-87055411

2319071

-13985915

-23518637

365653

426280

150418

967092

232526 469300

151970

8834728

-469971 -676182 85537 1116339 126158

4465

819

40799

420592

1088970

87341

71877

176958

1931196

1304505

-11669667

-10408283

29766

-29766

250000

100000

895556

230000

12500

518964

499900

61238

1660220

1889144

11756563

14545805

940731

767962

4119

25013050

50040

13783

-11665548

14575001

12066929

2201562

451421

16790346

1. NATURE OF OPERATIONS Biotricity Inc. (formerly MetaSolutions, Inc.) (the “Company” or “Biotricity”) was incorporated under the laws of the State of Nevada on August 29, 2012. iMedical Innovations Inc. (“iMedical”) was incorporated on July 3, 2014 under the laws of the Province of Ontario, Canada and became a wholly-owned subsidiary of Biotricity through reverse take-over on February 2, 2016. Both the Company and iMedical are engaged in research and development activities within the remote monitoring segment of preventative care. They are focused on a realizable healthcare business model that has an existing market and commercialization pathway. As such, its efforts to date have been devoted to building and commercializing an ecosystem of technologies that enable access to this market.

2. BASIS OF PRESENTATION, MEASUREMENT AND CONSOLIDATION The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) for interim financial information and the Securities and Exchange Commission (“SEC”) instructions to Form 10-Q and Article 8 of SEC Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete consolidated financial statements and should be read in conjunction with Biotricity’s audited consolidated financial statements for the years ended March 31, 2022 and 2021 and their accompanying notes. The accompanying unaudited condensed consolidated financial statements are expressed in United States dollars (“USD”). In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of financial position and results of operations for the interim periods presented have been reflected herein. Operating results for the interim periods presented herein are not necessarily indicative of the results that may be expected for the year ending March 31, 2023. The Company’s fiscal year-end is March 31. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. Significant intercompany accounts and transactions have been eliminated. Certain prior year amounts related to general and administrative expenses and other (expense) income line items on the condensed consolidated statements of operations and comprehensive loss have been reclassified to conform to the current year’s presentation. Liquidity and Basis of Presentation The Company is in the early stages of commercializing its first product and is concurrently in development mode, operating a research and development program in order to develop, obtain regulatory clearance for, and commercialize other proposed products. The Company has incurred recurring losses from operations, and as at December 31, 2022, had an accumulated deficit of $107,713,387 and a working capital deficiency of $2,496,289. Management anticipates the Company will continue on its revenue growth trajectory and improve its liquidity through continued business development and after additional equity or debt capitalization of the Company. On August 30, 2021, the Company completed an underwritten public offering of its common stock that concurrently facilitated its listing on the Nasdaq Capital Market. Prior to listing on the Nasdaq Capital Market, the Company had also filed a shelf Registration Statement on Form S-3 (No. 333-255544) with the Securities and Exchange Commission on April 27, 2021, which was declared effective on May 4, 2021. This may help facilitate better transactional preparedness when the Company seeks to issue equity or debt to potential investors, since it continues to allow the Company to offer its shares to investors only by means of a prospectus, including a prospectus supplement, which forms part of an effective registration statement. As such, the Company has developed and continues to pursue sources of funding that management believes will be sufficient to support the Company’s operating plan and alleviate any substantial doubt as to its ability to meet its obligations at least for a period of one year from the date of these condensed consolidated financial statements. During the fiscal quarter ended June 30, 2021, the Company raised $499,900 through government EIDL loan. In addition, during the fiscal quarter ended September 30, 2021, the Company raised total net proceeds of $14,545,805 through the underwritten public offering that was concurrent with its listing onto the Nasdaq Capital Markets. Furthermore, during the fiscal quarter ended December 31, 2021, the Company raised an additional net proceeds of $11,756,563 through a term loan transaction (Note 6). During the fiscal quarter ended December 31, 2022, the Company raised short-term loans and promissory notes with net proceeds of $1,889,144 from various lenders. BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022 (Unaudited) (Expressed in US dollars) As we proceed with the commercialization of the Bioflux, Biotres, and Biocare product development, we expect to continue to devote significant resources on capital expenditures, as well as research and development costs and operations, marketing and sales expenditures. Based on the above facts and assumptions, we believe our existing cash, along with anticipated near-term equity financings, will be sufficient to meet our needs for the next twelve months from the filing date of this report. However, we will need to seek additional debt or equity capital to respond to business opportunities and challenges, including our ongoing operating expenses, protecting our intellectual property, developing or acquiring new lines of business and enhancing our operating infrastructure. The terms of our future financings may be dilutive to, or otherwise adversely affect, holders of our common stock. We may also seek additional funds through arrangements with collaborators or other third parties. There can be no assurance we will be able to raise this additional capital on acceptable terms, or at all. If we are unable to obtain additional funding on a timely basis, we may be required to modify our operating plan and otherwise curtail or slow the pace of development and commercialization of our proposed product lines. In December 2019, a novel strain of coronavirus (COVID-19) emerged in Wuhan, Hubei Province, China and spread globally, causing significant disruption to the global and US economy. On March 20, 2020, the Company announced the precautionary measures taken as well as announcing the business impact related to the coronavirus (COVID-19) pandemic. Though its operations have since returned to a normal state, the extent to which the COVID-19 pandemic will continue to affect the economy and the Company’s operations remains unclear and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of any future ongoing COVID-19 outbreaks, new information which may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced patient traffic and reduced operations. The measures taken to date may continue to impact the Company’s fiscal year 2023 business and potentially beyond. Management expects that all of its business segments, across all of its geographies, may be impacted to some degree, but the significance of the full long-term impact of the COVID-19 outbreak on the Company’s business and the duration for which it may have an impact cannot be determined at this time.

-107713387

2496289

499900

14545805

11756563

1889144

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Revenue Recognition The Company adopted Accounting Standards Codification Topic 606, “Revenue from Contracts with Customers” (“ASC 606”) on April 1, 2018. In accordance with ASC 606, revenue is recognized when promised goods or services are transferred to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services by applying the core principles – 1) identify the contract with a customer, 2) identify the performance obligations in the contract, 3) determine the transaction price, 4) allocate the transaction price to performance obligations in the contract, and 5) recognize revenue as performance obligations are satisfied. BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022 (Unaudited) (Expressed in US dollars) Both the Bioflux mobile cardiac telemetry device, and the Biotres device are wearable devices. The cardiac data that the devices monitor and collect is curated and analyzed by the Company’s proprietary algorithms and then securely communicated to a remote monitoring facility for electronic reporting and conveyance to the patient’s prescribing physician or other certified cardiac medical professional. Revenues earned are comprised of device sales revenues and technology fee revenues (technology as a service). The devices, together with their licensed software, are available for sale to the medical center or physician, who is responsible for the delivery of clinical diagnosis and therapy. The remote monitoring, data collection and reporting services performed by the technology culminate in a patient study that is generally billable when it is complete and is issued to the physician. In order to recognize revenue, management considers whether or not the following criteria are met: persuasive evidence of a commercial arrangement exists, and delivery has occurred or services have been rendered. For sales of devices, which are invoiced directly, additional revenue recognition criteria include that the price is fixed and determinable and collectability is reasonably assured; for device sales contracts with terms of more than one year, the Company recognizes any significant financing component as revenue over the contractual period using the effective interest method, and the associated interest income is reflected accordingly on the statement of operations and included in other income; for revenue that is earned based on customer usage of the proprietary software to render a patient’s cardiac study, the Company recognizes revenue when the study ends based on a fixed billing rate. Costs associated with providing the services are recorded as the service is provided regardless of whether or when revenue is recognized. The Company may also earn service-related revenue from contracts with other counterparties with which it consults. This contract work is separate and distinct from services provided to clinical customers, but may be with a reseller or other counterparties that are working to establish their operations in foreign jurisdictions or ancillary products or market segments in which the Company has expertise and may eventually conduct business. <p id="xdx_89B_eus-gaap--ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_zijRtYeQ6e52" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognized the following forms of revenue for the three and nine months ended December 31, 2022 and 2021: SCHEDULE OF REVENUE RECOGNITION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20221001__20221231_zSKyhSuR2Q7i" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For Three Months Ended December 31, 2022 $</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20211001__20211231_zl8HnpwU2Zs7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For Three Months Ended December 31, 2021 $</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20220401__20221231_zyI9T3BPWMWg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For Nine Months Ended December 31, 2022 $</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20210401__20211231_z55msJF8r8pi" style="border-bottom: Black 1.5pt solid; text-align: center">For Nine Months Ended December 31, 2021 $</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_400_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--TechnologyFeesSalesMember_zrX9osVjDnTl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Technology fee sales</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">2,253,187</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">1,413,790</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">6,240,042</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">4,365,292</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--DeviceSalesMember_ztAPS1t7r1Ab" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Device sales</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">205,994</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">266,318</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">656,580</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">886,235</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ServiceRelatedAndOtherRevenueMember_zt2SeV4wZJkj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Service-related and other revenue</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">250,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">250,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zbjGJBnHAtw5" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> Revenue</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">2,459,181</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,930,108</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">6,896,622</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">5,501,527</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Inventory Inventory is stated at the lower of cost and market value, cost being determined on a weighted average cost basis. Market value of our inventory, which is all purchased finished goods, is determined based on its estimated net realizable value, which is generally the selling price less normally predictable costs of disposal and transportation. The Company records write-downs of inventory that is obsolete or in excess of anticipated demand or market value based on consideration of product lifecycle stage, technology trends, product development plans and assumptions about future demand and market conditions. Actual demand may differ from forecasted demand, and such differences may have a material effect on recorded inventory values. Inventory write-downs are charged to cost of revenue and establish a new cost basis for the inventory. Significant accounting estimates and assumptions The preparation of the condensed consolidated financial statements requires the use of estimates and assumptions to be made in applying the accounting policies that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities. The estimates and related assumptions are based on previous experiences and other factors considered reasonable under the circumstances, the results of which form the basis for making the assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources. BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022 (Unaudited) (Expressed in US dollars) The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods. Significant accounts that require estimates as the basis for determining the stated amounts include share-based compensation, impairment analysis and fair value of warrants, structured notes, convertible debt and conversion liabilities. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Fair value of stock options</td></tr> </table> The Company measures the cost of equity-settled transactions with employees by reference to the fair value of equity instruments at the date at which they are granted. Estimating fair value for share-based payments requires determining the most appropriate valuation model for a grant of such instruments, which is dependent on the terms and conditions of the grant. The estimate also requires determining the most appropriate inputs to the Black-Scholes option pricing model, including the expected life of the instrument, risk-free rate, volatility, and dividend yield. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Fair value of warrants</td></tr> </table> In determining the fair value of the warrant issued for services and issue pursuant to financing transactions, the Company used the Black-Scholes option pricing model with the following assumptions: volatility rate, risk-free rate, and the remaining expected life of the warrants that are classified under equity. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Fair value of derivative liabilities</td></tr> </table> In determining the fair values of the derivative liabilities from the conversion and redemption features, the Company used valuation models with the following assumptions: dividend yields, volatility, risk-free rate and the remaining expected life. Changes in those assumptions and inputs could in turn impact the fair value of the derivative liabilities and can have a material impact on the reported loss and comprehensive loss for the applicable reporting period. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Functional currency</td></tr> </table> Determining the appropriate functional currencies for entities in the Company requires analysis of various factors, including the currencies and country-specific factors that mainly influence labor, materials, and other operating expenses. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Useful life of property and equipment</td></tr> </table> The Company employs significant estimates to determine the estimated useful lives of property and equipment, considering industry trends such as technological advancements, past experience, expected use and review of asset useful lives. The Company makes estimates when determining depreciation methods, depreciation rates and asset useful lives, which requires considering industry trends and company-specific factors. The Company reviews depreciation methods, useful lives and residual values annually or when circumstances change and adjusts its depreciation methods and assumptions prospectively. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Provisions</td></tr> </table> Provisions are recognized when the Company has a present obligation, legal or constructive, as a result of a previous event, if it is probable that the Company will be required to settle the obligation and a reliable estimate can be made of the obligation. The amount recognized is the best estimate of the expenditure required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligations. Provisions are reviewed at the end of each reporting period and adjusted to reflect the current best estimate of the expected future cash flows. BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022 (Unaudited) (Expressed in US dollars) <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Contingencies</td></tr> </table> Contingencies can be either possible assets or possible liabilities arising from past events, which, by their nature, will be resolved only when one or more uncertain future events occur or fail to occur. The assessment of the existence and potential impact of contingencies inherently involves the exercise of significant judgment and the use of estimates regarding the outcome of future events. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Inventory obsolescence</td></tr> </table> Inventories are stated at the lower of cost and market value. Market value of our inventory, which is all purchased finished goods, is determined based on its estimated net realizable value, which is generally the selling price less normally predictable costs of disposal and transportation. The Company estimates net realizable value as the amount at which inventories are expected to be sold, taking into consideration fluctuations in retail prices less estimated costs necessary to make the sale. Inventories are written down to net realizable value when the cost of inventories is estimated to be unrecoverable due to obsolescence, damage, or declining selling prices. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Income and other taxes</td></tr> </table> The calculation of current and deferred income taxes requires the Company to make estimates and assumptions and to exercise judgment regarding the carrying values of assets and liabilities which are subject to accounting estimates inherent in those balances, the interpretation of income tax legislation across various jurisdictions, expectations about future operating results, the timing of reversal of temporary differences and possible audits of income tax filings by the tax authorities. In addition, when the Company incurs losses for income tax purposes, it assesses the probability of taxable income being available in the future based on its budgeted forecasts. These forecasts are adjusted to take into account certain non-taxable income and expenses and specific rules on the use of unused credits and tax losses. When the forecasts indicate that sufficient future taxable income will be available to deduct the temporary differences, a deferred tax asset is recognized for all deductible temporary differences. Changes or differences in underlying estimates or assumptions may result in changes to the current or deferred income tax balances on the condensed consolidated balance sheets, a charge or credit to income tax expense included as part of net income (loss) and may result in cash payments or receipts. Judgment includes consideration of the Company’s future cash requirements in its tax jurisdictions. All income, capital and commodity tax filings are subject to audits and reassessments. Changes in interpretations or judgments may result in a change in the Company’s income, capital, or commodity tax provisions in the future. The amount of such a change cannot be reasonably estimated. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Incremental borrowing rate for lease</td></tr> </table> The determination of the Company’s lease obligation and right-of-use asset depends on certain assumptions, which include the selection of the discount rate. The discount rate is set by reference to the Company’s incremental borrowing rate. Significant assumptions are required to be made when determining which borrowing rates to apply in this determination. Changes in the assumptions used may have a significant effect on the Company’s condensed consolidated financial statements. BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022 (Unaudited) (Expressed in US dollars) Earnings (Loss) Per Share The Company has adopted the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 260-10 which provides for calculation of “basic” and “diluted” earnings per share. Basic loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted earnings or loss per share of common stock is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional shares from the assumed exercise of any common stock equivalents, if dilutive. The Company’s warrants, options, convertible promissory notes, convertible preferred stock, shares to be issued and restricted stock awards while outstanding are considered common stock equivalents for this purpose. Diluted earnings is computed utilizing the treasury method for the warrants, stock options, shares to be issued and restricted stock awards. Diluted earnings with respect to the convertible promissory notes and convertible preferred stock utilizing the if-converted method was not applicable during the periods presented as no conditions required for conversion had occurred. No incremental common stock equivalents were included in calculating diluted loss per share because such inclusion would be anti-dilutive given the net loss reported for the periods presented. Cash Cash includes cash on hand and balances with banks. Foreign Currency Translation The functional currency of the Company’s Canadian-based subsidiary is the Canadian dollar and the US-based parent is the U.S. dollar. Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the balance sheet date. Non-monetary assets and liabilities are translated using the historical rate on the date of the transaction. All exchange gains or losses arising from translation of these foreign currency transactions are included in net income (loss) for the year. In translating the financial statements of the Company’s Canadian subsidiaries from their functional currency into the Company’s reporting currency of United States dollars, condensed consolidated balance sheet accounts are translated using the closing exchange rate in effect at the balance sheet date and income and expense accounts are translated using an average exchange rate prevailing during the reporting period. Adjustments resulting from the translation, if any, are included in accumulated other comprehensive loss in stockholders’ deficiency. The Company has not, to the date of these condensed consolidated financial statements, entered into derivative instruments to offset the impact of foreign currency fluctuations. Accounts Receivable Accounts receivable consists of amounts due to the Company from medical facilities, which receive reimbursement from institutions and third-party government and commercial payors and their related patients, as a result of the Company’s normal business activities. Accounts receivable is reported on the condensed consolidated balance sheets net of an estimated allowance for doubtful accounts. The Company establishes an allowance for doubtful accounts for estimated uncollectible receivables based on historical experience, assessment of specific risk, review of outstanding invoices, and various assumptions and estimates that are believed to be reasonable under the circumstances, and recognizes the provision as a component of selling, general and administrative expenses. Uncollectible accounts are written off against the allowance after appropriate collection efforts have been exhausted and when it is deemed that a balance is uncollectible. BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022 (Unaudited) (Expressed in US dollars) Fair Value of Financial Instruments ASC 820 defines fair value, establishes a framework for measuring fair value and expands required disclosure about fair value measurements of assets and liabilities. ASC 820-10 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: ● Level 1 – Valuation based on quoted market prices in active markets for identical assets or liabilities. ● Level 2 – Valuation based on quoted market prices for similar assets and liabilities in active markets. ● Level 3 – Valuation based on unobservable inputs that are supported by little or no market activity, therefore requiring management’s best estimate of what market participants would use as fair value. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments or interest rates that are comparable to market rates. These financial instruments include cash, accounts receivable, deposits and other receivables, convertible promissory notes and short term loans, federally-guaranteed loans, term loans and accounts payable and accrued liabilities. The Company’s cash and derivative liabilities, which are carried at fair values, are classified as a Level 1 and Level 3, respectively. The Company’s bank accounts are maintained with financial institutions of reputable credit, therefore, bear minimal credit risk. Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful lives of the assets. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. Depreciation of property and equipment is provided using the straight-line method for substantially all assets with estimated lives as follow: SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 35%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: justify">Office equipment</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: justify"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20220401__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zkcgMKeIz434" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 years</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">Leasehold improvement</td> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20220401__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zgkgdQhIAXT5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 years</td></tr> </table> Impairment for Long-Lived Assets The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment, which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. ASC 360 requires impairment losses to be recorded on long-lived assets, including right-of-use assets, used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair values are reduced for the cost of disposal. Based on its review at December 31, 2022 and 2021, the Company believes there was no impairment of its long-lived assets. BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022 (Unaudited) (Expressed in US dollars) Leases The Company is the lessee in a lease contract when the Company obtains the right to use the asset. Operating leases are included in the line items right-of-use asset, lease obligation, current, and lease obligation, long-term in the condensed consolidated balance sheet. Right-of-use (“ROU”) asset represents the Company’s right to use an underlying asset for the lease term and lease obligations represent the Company’s obligations to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the condensed consolidated balance sheet and are expensed on a straight-line basis over the lease term in the condensed consolidated statement of operations. The Company determines the lease term by agreement with lessor. As the Company’s lease does not provide implicit interest rate, the Company uses the Company’s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. Refer to Note 10 for further discussion. Income Taxes The Company accounts for income taxes in accordance with ASC 740. The Company provides for Federal, State and Provincial income taxes payable, as well as for those deferred because of the timing differences between reporting income and expenses for financial statement purposes versus tax purposes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recoverable or settled. The effect of a change in tax rates is recognized as income or expense in the period of the change. A valuation allowance is established, when necessary, to reduce deferred income tax assets to the amount that is more likely than not to be realized. Research and Development Research and development costs, which relate primarily to product and software development, are charged to operations as incurred. Under certain research and development arrangements with third parties, the Company may be required to make payments that are contingent on the achievement of specific developmental, regulatory and/or commercial milestones. Before a product receives regulatory approval, milestone payments made to third parties are expensed when the milestone is achieved. Milestone payments made to third parties after regulatory approval is received are capitalized and amortized over the estimated useful life of the approved product. Stock Based Compensation The Company accounts for share-based payments in accordance with the provision of ASC 718, which requires that all share-based payments issued to acquire goods or services, including grants of employee stock options, be recognized in the condensed consolidated statements of operations and comprehensive loss based on their fair values, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Compensation expense related to share-based awards is recognized over the requisite service period, which is generally the vesting period. The Company accounts for stock based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the guidelines in ASC 505-50. The Company issues compensatory shares for services including, but not limited to, executive, management, accounting, operations, corporate communication, financial and administrative consulting services. BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022 (Unaudited) (Expressed in US dollars) Convertible Notes Payable and Derivative Instruments The Company has adopted the provisions of ASU 2017-11 to account for the down round features of warrants issued with private placements effective as of April 1, 2017. In doing so, warrants with a down round feature previously treated as derivative liabilities in the condensed consolidated balance sheet and measured at fair value are henceforth treated as equity, with no adjustment for changes in fair value at each reporting period. Previously, the Company accounted for conversion options embedded in convertible notes in accordance with ASC 815. ASC 815 generally requires companies to bifurcate conversion options embedded in convertible notes from their host instruments and to account for them as free-standing derivative financial instruments. ASC 815 provides for an exception to this rule when convertible notes, as host instruments, are deemed to be conventional, as defined by ASC 815-40. The Company accounts for convertible notes deemed conventional and conversion options embedded in non-conventional convertible notes which qualify as equity under ASC 815, in accordance with the provisions of ASC 470-20, which provides guidance on accounting for convertible securities with beneficial conversion features. Accordingly, the Company records, as a discount to convertible notes, the intrinsic value of such conversion options based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt. Preferred Shares Extinguishments The Company accounted for preferred stock redemptions and conversions in accordance to ASU-260-10-S99. For preferred stock redemptions and conversion, the difference between the fair value of consideration transferred to the holders of the preferred stock and the carrying amount of the preferred stock is accounted as deemed dividend distribution and subtracted from net loss. Recently Issued Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, “Financial Instruments - Credit Losses (Topic 326) - Measurement of Credit Losses on Financial Instruments.” This pronouncement, along with subsequent ASUs issued to clarify provisions of ASU 2016-13, changes the impairment model for most financial assets and will require the use of an “expected loss” model for instruments measured at amortized cost. Under this model, entities will be required to estimate the lifetime expected credit loss on such instruments and record an allowance to offset the amortized cost basis of the financial asset, resulting in a net presentation of the amount expected to be collected on the financial asset. In developing the estimate for lifetime expected credit loss, entities must incorporate historical experience, current conditions, and reasonable and supportable forecasts. This pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2019. On November 19, 2019, the FASB issued ASU No. 2019-10, Financial Instruments—Credit Losses (Topic 326), finalized various effective date delays for private companies, not-for-profit organizations, and certain smaller reporting companies applying the credit losses (CECL), the revised effective for fiscal years beginning after December 15, 2022. In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, Income Taxes, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. ASU 2019-12 is effective for fiscal years beginning after December 15, 2021. Most amendments within the standard are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. There is no significant impact from adopting ASU 2019-12 on the Company’s financial condition, results of operations, and cash flows. In April 2021, The FASB issued ASU 2021-04 to codify the final consensus reached by the Emerging Issues Task Force (EITF) on how an issuer should account for modifications made to equity-classified written call options (hereafter referred to as a warrant to purchase the issuer’s common stock). The guidance in the ASU requires the issuer to treat a modification of an equity-classified warrant that does not cause the warrant to become liability-classified as an exchange of the original warrant for a new warrant. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the warrant or as termination of the original warrant and issuance of a new warrant. The Company adopted this guidance for the fiscal year beginning April 1, 2022. There is no significant impact from adopting ASU 2021-04 on the Company’s financial condition, results of operations, and cash flows. BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022 (Unaudited) (Expressed in US dollars) The Company continue to evaluate the impact of the new accounting pronouncement, including enhanced disclosure requirements, on our business processes, controls and systems.

Revenue Recognition The Company adopted Accounting Standards Codification Topic 606, “Revenue from Contracts with Customers” (“ASC 606”) on April 1, 2018. In accordance with ASC 606, revenue is recognized when promised goods or services are transferred to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services by applying the core principles – 1) identify the contract with a customer, 2) identify the performance obligations in the contract, 3) determine the transaction price, 4) allocate the transaction price to performance obligations in the contract, and 5) recognize revenue as performance obligations are satisfied. BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022 (Unaudited) (Expressed in US dollars) Both the Bioflux mobile cardiac telemetry device, and the Biotres device are wearable devices. The cardiac data that the devices monitor and collect is curated and analyzed by the Company’s proprietary algorithms and then securely communicated to a remote monitoring facility for electronic reporting and conveyance to the patient’s prescribing physician or other certified cardiac medical professional. Revenues earned are comprised of device sales revenues and technology fee revenues (technology as a service). The devices, together with their licensed software, are available for sale to the medical center or physician, who is responsible for the delivery of clinical diagnosis and therapy. The remote monitoring, data collection and reporting services performed by the technology culminate in a patient study that is generally billable when it is complete and is issued to the physician. In order to recognize revenue, management considers whether or not the following criteria are met: persuasive evidence of a commercial arrangement exists, and delivery has occurred or services have been rendered. For sales of devices, which are invoiced directly, additional revenue recognition criteria include that the price is fixed and determinable and collectability is reasonably assured; for device sales contracts with terms of more than one year, the Company recognizes any significant financing component as revenue over the contractual period using the effective interest method, and the associated interest income is reflected accordingly on the statement of operations and included in other income; for revenue that is earned based on customer usage of the proprietary software to render a patient’s cardiac study, the Company recognizes revenue when the study ends based on a fixed billing rate. Costs associated with providing the services are recorded as the service is provided regardless of whether or when revenue is recognized. The Company may also earn service-related revenue from contracts with other counterparties with which it consults. This contract work is separate and distinct from services provided to clinical customers, but may be with a reseller or other counterparties that are working to establish their operations in foreign jurisdictions or ancillary products or market segments in which the Company has expertise and may eventually conduct business. <p id="xdx_89B_eus-gaap--ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_zijRtYeQ6e52" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognized the following forms of revenue for the three and nine months ended December 31, 2022 and 2021: SCHEDULE OF REVENUE RECOGNITION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20221001__20221231_zSKyhSuR2Q7i" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For Three Months Ended December 31, 2022 $</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20211001__20211231_zl8HnpwU2Zs7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For Three Months Ended December 31, 2021 $</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20220401__20221231_zyI9T3BPWMWg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For Nine Months Ended December 31, 2022 $</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20210401__20211231_z55msJF8r8pi" style="border-bottom: Black 1.5pt solid; text-align: center">For Nine Months Ended December 31, 2021 $</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_400_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--TechnologyFeesSalesMember_zrX9osVjDnTl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Technology fee sales</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">2,253,187</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">1,413,790</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">6,240,042</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">4,365,292</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--DeviceSalesMember_ztAPS1t7r1Ab" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Device sales</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">205,994</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">266,318</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">656,580</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">886,235</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ServiceRelatedAndOtherRevenueMember_zt2SeV4wZJkj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Service-related and other revenue</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">250,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">250,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zbjGJBnHAtw5" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> Revenue</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">2,459,181</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,930,108</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">6,896,622</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">5,501,527</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

<p id="xdx_89B_eus-gaap--ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_zijRtYeQ6e52" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognized the following forms of revenue for the three and nine months ended December 31, 2022 and 2021: SCHEDULE OF REVENUE RECOGNITION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20221001__20221231_zSKyhSuR2Q7i" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For Three Months Ended December 31, 2022 $</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20211001__20211231_zl8HnpwU2Zs7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For Three Months Ended December 31, 2021 $</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20220401__20221231_zyI9T3BPWMWg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For Nine Months Ended December 31, 2022 $</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20210401__20211231_z55msJF8r8pi" style="border-bottom: Black 1.5pt solid; text-align: center">For Nine Months Ended December 31, 2021 $</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_400_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--TechnologyFeesSalesMember_zrX9osVjDnTl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Technology fee sales</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">2,253,187</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">1,413,790</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">6,240,042</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">4,365,292</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--DeviceSalesMember_ztAPS1t7r1Ab" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Device sales</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">205,994</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">266,318</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">656,580</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">886,235</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ServiceRelatedAndOtherRevenueMember_zt2SeV4wZJkj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Service-related and other revenue</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">250,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">250,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zbjGJBnHAtw5" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> Revenue</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">2,459,181</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,930,108</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">6,896,622</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">5,501,527</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

2253187

1413790

6240042

4365292

205994

266318

656580

886235

250000

2459181

1930108

6896622

5501527

Inventory Inventory is stated at the lower of cost and market value, cost being determined on a weighted average cost basis. Market value of our inventory, which is all purchased finished goods, is determined based on its estimated net realizable value, which is generally the selling price less normally predictable costs of disposal and transportation. The Company records write-downs of inventory that is obsolete or in excess of anticipated demand or market value based on consideration of product lifecycle stage, technology trends, product development plans and assumptions about future demand and market conditions. Actual demand may differ from forecasted demand, and such differences may have a material effect on recorded inventory values. Inventory write-downs are charged to cost of revenue and establish a new cost basis for the inventory.

Significant accounting estimates and assumptions The preparation of the condensed consolidated financial statements requires the use of estimates and assumptions to be made in applying the accounting policies that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities. The estimates and related assumptions are based on previous experiences and other factors considered reasonable under the circumstances, the results of which form the basis for making the assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources. BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022 (Unaudited) (Expressed in US dollars) The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods. Significant accounts that require estimates as the basis for determining the stated amounts include share-based compensation, impairment analysis and fair value of warrants, structured notes, convertible debt and conversion liabilities. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Fair value of stock options</td></tr> </table> The Company measures the cost of equity-settled transactions with employees by reference to the fair value of equity instruments at the date at which they are granted. Estimating fair value for share-based payments requires determining the most appropriate valuation model for a grant of such instruments, which is dependent on the terms and conditions of the grant. The estimate also requires determining the most appropriate inputs to the Black-Scholes option pricing model, including the expected life of the instrument, risk-free rate, volatility, and dividend yield. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Fair value of warrants</td></tr> </table> In determining the fair value of the warrant issued for services and issue pursuant to financing transactions, the Company used the Black-Scholes option pricing model with the following assumptions: volatility rate, risk-free rate, and the remaining expected life of the warrants that are classified under equity. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Fair value of derivative liabilities</td></tr> </table> In determining the fair values of the derivative liabilities from the conversion and redemption features, the Company used valuation models with the following assumptions: dividend yields, volatility, risk-free rate and the remaining expected life. Changes in those assumptions and inputs could in turn impact the fair value of the derivative liabilities and can have a material impact on the reported loss and comprehensive loss for the applicable reporting period. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Functional currency</td></tr> </table> Determining the appropriate functional currencies for entities in the Company requires analysis of various factors, including the currencies and country-specific factors that mainly influence labor, materials, and other operating expenses. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Useful life of property and equipment</td></tr> </table> The Company employs significant estimates to determine the estimated useful lives of property and equipment, considering industry trends such as technological advancements, past experience, expected use and review of asset useful lives. The Company makes estimates when determining depreciation methods, depreciation rates and asset useful lives, which requires considering industry trends and company-specific factors. The Company reviews depreciation methods, useful lives and residual values annually or when circumstances change and adjusts its depreciation methods and assumptions prospectively. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Provisions</td></tr> </table> Provisions are recognized when the Company has a present obligation, legal or constructive, as a result of a previous event, if it is probable that the Company will be required to settle the obligation and a reliable estimate can be made of the obligation. The amount recognized is the best estimate of the expenditure required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligations. Provisions are reviewed at the end of each reporting period and adjusted to reflect the current best estimate of the expected future cash flows. BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022 (Unaudited) (Expressed in US dollars) <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Contingencies</td></tr> </table> Contingencies can be either possible assets or possible liabilities arising from past events, which, by their nature, will be resolved only when one or more uncertain future events occur or fail to occur. The assessment of the existence and potential impact of contingencies inherently involves the exercise of significant judgment and the use of estimates regarding the outcome of future events. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Inventory obsolescence</td></tr> </table> Inventories are stated at the lower of cost and market value. Market value of our inventory, which is all purchased finished goods, is determined based on its estimated net realizable value, which is generally the selling price less normally predictable costs of disposal and transportation. The Company estimates net realizable value as the amount at which inventories are expected to be sold, taking into consideration fluctuations in retail prices less estimated costs necessary to make the sale. Inventories are written down to net realizable value when the cost of inventories is estimated to be unrecoverable due to obsolescence, damage, or declining selling prices. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Income and other taxes</td></tr> </table> The calculation of current and deferred income taxes requires the Company to make estimates and assumptions and to exercise judgment regarding the carrying values of assets and liabilities which are subject to accounting estimates inherent in those balances, the interpretation of income tax legislation across various jurisdictions, expectations about future operating results, the timing of reversal of temporary differences and possible audits of income tax filings by the tax authorities. In addition, when the Company incurs losses for income tax purposes, it assesses the probability of taxable income being available in the future based on its budgeted forecasts. These forecasts are adjusted to take into account certain non-taxable income and expenses and specific rules on the use of unused credits and tax losses. When the forecasts indicate that sufficient future taxable income will be available to deduct the temporary differences, a deferred tax asset is recognized for all deductible temporary differences. Changes or differences in underlying estimates or assumptions may result in changes to the current or deferred income tax balances on the condensed consolidated balance sheets, a charge or credit to income tax expense included as part of net income (loss) and may result in cash payments or receipts. Judgment includes consideration of the Company’s future cash requirements in its tax jurisdictions. All income, capital and commodity tax filings are subject to audits and reassessments. Changes in interpretations or judgments may result in a change in the Company’s income, capital, or commodity tax provisions in the future. The amount of such a change cannot be reasonably estimated. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Incremental borrowing rate for lease</td></tr> </table> The determination of the Company’s lease obligation and right-of-use asset depends on certain assumptions, which include the selection of the discount rate. The discount rate is set by reference to the Company’s incremental borrowing rate. Significant assumptions are required to be made when determining which borrowing rates to apply in this determination. Changes in the assumptions used may have a significant effect on the Company’s condensed consolidated financial statements. BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022 (Unaudited) (Expressed in US dollars)

Earnings (Loss) Per Share The Company has adopted the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 260-10 which provides for calculation of “basic” and “diluted” earnings per share. Basic loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted earnings or loss per share of common stock is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional shares from the assumed exercise of any common stock equivalents, if dilutive. The Company’s warrants, options, convertible promissory notes, convertible preferred stock, shares to be issued and restricted stock awards while outstanding are considered common stock equivalents for this purpose. Diluted earnings is computed utilizing the treasury method for the warrants, stock options, shares to be issued and restricted stock awards. Diluted earnings with respect to the convertible promissory notes and convertible preferred stock utilizing the if-converted method was not applicable during the periods presented as no conditions required for conversion had occurred. No incremental common stock equivalents were included in calculating diluted loss per share because such inclusion would be anti-dilutive given the net loss reported for the periods presented.

Cash Cash includes cash on hand and balances with banks.

Foreign Currency Translation The functional currency of the Company’s Canadian-based subsidiary is the Canadian dollar and the US-based parent is the U.S. dollar. Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the balance sheet date. Non-monetary assets and liabilities are translated using the historical rate on the date of the transaction. All exchange gains or losses arising from translation of these foreign currency transactions are included in net income (loss) for the year. In translating the financial statements of the Company’s Canadian subsidiaries from their functional currency into the Company’s reporting currency of United States dollars, condensed consolidated balance sheet accounts are translated using the closing exchange rate in effect at the balance sheet date and income and expense accounts are translated using an average exchange rate prevailing during the reporting period. Adjustments resulting from the translation, if any, are included in accumulated other comprehensive loss in stockholders’ deficiency. The Company has not, to the date of these condensed consolidated financial statements, entered into derivative instruments to offset the impact of foreign currency fluctuations.

Accounts Receivable Accounts receivable consists of amounts due to the Company from medical facilities, which receive reimbursement from institutions and third-party government and commercial payors and their related patients, as a result of the Company’s normal business activities. Accounts receivable is reported on the condensed consolidated balance sheets net of an estimated allowance for doubtful accounts. The Company establishes an allowance for doubtful accounts for estimated uncollectible receivables based on historical experience, assessment of specific risk, review of outstanding invoices, and various assumptions and estimates that are believed to be reasonable under the circumstances, and recognizes the provision as a component of selling, general and administrative expenses. Uncollectible accounts are written off against the allowance after appropriate collection efforts have been exhausted and when it is deemed that a balance is uncollectible. BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022 (Unaudited) (Expressed in US dollars)

Fair Value of Financial Instruments ASC 820 defines fair value, establishes a framework for measuring fair value and expands required disclosure about fair value measurements of assets and liabilities. ASC 820-10 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: ● Level 1 – Valuation based on quoted market prices in active markets for identical assets or liabilities. ● Level 2 – Valuation based on quoted market prices for similar assets and liabilities in active markets. ● Level 3 – Valuation based on unobservable inputs that are supported by little or no market activity, therefore requiring management’s best estimate of what market participants would use as fair value. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments or interest rates that are comparable to market rates. These financial instruments include cash, accounts receivable, deposits and other receivables, convertible promissory notes and short term loans, federally-guaranteed loans, term loans and accounts payable and accrued liabilities. The Company’s cash and derivative liabilities, which are carried at fair values, are classified as a Level 1 and Level 3, respectively. The Company’s bank accounts are maintained with financial institutions of reputable credit, therefore, bear minimal credit risk.

Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful lives of the assets. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. Depreciation of property and equipment is provided using the straight-line method for substantially all assets with estimated lives as follow: SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 35%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: justify">Office equipment</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: justify"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20220401__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zkcgMKeIz434" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 years</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">Leasehold improvement</td> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20220401__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zgkgdQhIAXT5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 years</td></tr> </table>

SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 35%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: justify">Office equipment</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: justify"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20220401__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zkcgMKeIz434" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 years</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">Leasehold improvement</td> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20220401__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zgkgdQhIAXT5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 years</td></tr> </table>

5 years

Impairment for Long-Lived Assets The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment, which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. ASC 360 requires impairment losses to be recorded on long-lived assets, including right-of-use assets, used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair values are reduced for the cost of disposal. Based on its review at December 31, 2022 and 2021, the Company believes there was no impairment of its long-lived assets. BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022 (Unaudited) (Expressed in US dollars)

Leases The Company is the lessee in a lease contract when the Company obtains the right to use the asset. Operating leases are included in the line items right-of-use asset, lease obligation, current, and lease obligation, long-term in the condensed consolidated balance sheet. Right-of-use (“ROU”) asset represents the Company’s right to use an underlying asset for the lease term and lease obligations represent the Company’s obligations to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the condensed consolidated balance sheet and are expensed on a straight-line basis over the lease term in the condensed consolidated statement of operations. The Company determines the lease term by agreement with lessor. As the Company’s lease does not provide implicit interest rate, the Company uses the Company’s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. Refer to Note 10 for further discussion.

Income Taxes The Company accounts for income taxes in accordance with ASC 740. The Company provides for Federal, State and Provincial income taxes payable, as well as for those deferred because of the timing differences between reporting income and expenses for financial statement purposes versus tax purposes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recoverable or settled. The effect of a change in tax rates is recognized as income or expense in the period of the change. A valuation allowance is established, when necessary, to reduce deferred income tax assets to the amount that is more likely than not to be realized.

Research and Development Research and development costs, which relate primarily to product and software development, are charged to operations as incurred. Under certain research and development arrangements with third parties, the Company may be required to make payments that are contingent on the achievement of specific developmental, regulatory and/or commercial milestones. Before a product receives regulatory approval, milestone payments made to third parties are expensed when the milestone is achieved. Milestone payments made to third parties after regulatory approval is received are capitalized and amortized over the estimated useful life of the approved product.

Stock Based Compensation The Company accounts for share-based payments in accordance with the provision of ASC 718, which requires that all share-based payments issued to acquire goods or services, including grants of employee stock options, be recognized in the condensed consolidated statements of operations and comprehensive loss based on their fair values, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Compensation expense related to share-based awards is recognized over the requisite service period, which is generally the vesting period. The Company accounts for stock based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the guidelines in ASC 505-50. The Company issues compensatory shares for services including, but not limited to, executive, management, accounting, operations, corporate communication, financial and administrative consulting services. BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022 (Unaudited) (Expressed in US dollars)

Convertible Notes Payable and Derivative Instruments The Company has adopted the provisions of ASU 2017-11 to account for the down round features of warrants issued with private placements effective as of April 1, 2017. In doing so, warrants with a down round feature previously treated as derivative liabilities in the condensed consolidated balance sheet and measured at fair value are henceforth treated as equity, with no adjustment for changes in fair value at each reporting period. Previously, the Company accounted for conversion options embedded in convertible notes in accordance with ASC 815. ASC 815 generally requires companies to bifurcate conversion options embedded in convertible notes from their host instruments and to account for them as free-standing derivative financial instruments. ASC 815 provides for an exception to this rule when convertible notes, as host instruments, are deemed to be conventional, as defined by ASC 815-40. The Company accounts for convertible notes deemed conventional and conversion options embedded in non-conventional convertible notes which qualify as equity under ASC 815, in accordance with the provisions of ASC 470-20, which provides guidance on accounting for convertible securities with beneficial conversion features. Accordingly, the Company records, as a discount to convertible notes, the intrinsic value of such conversion options based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt.

Preferred Shares Extinguishments The Company accounted for preferred stock redemptions and conversions in accordance to ASU-260-10-S99. For preferred stock redemptions and conversion, the difference between the fair value of consideration transferred to the holders of the preferred stock and the carrying amount of the preferred stock is accounted as deemed dividend distribution and subtracted from net loss.

Recently Issued Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, “Financial Instruments - Credit Losses (Topic 326) - Measurement of Credit Losses on Financial Instruments.” This pronouncement, along with subsequent ASUs issued to clarify provisions of ASU 2016-13, changes the impairment model for most financial assets and will require the use of an “expected loss” model for instruments measured at amortized cost. Under this model, entities will be required to estimate the lifetime expected credit loss on such instruments and record an allowance to offset the amortized cost basis of the financial asset, resulting in a net presentation of the amount expected to be collected on the financial asset. In developing the estimate for lifetime expected credit loss, entities must incorporate historical experience, current conditions, and reasonable and supportable forecasts. This pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2019. On November 19, 2019, the FASB issued ASU No. 2019-10, Financial Instruments—Credit Losses (Topic 326), finalized various effective date delays for private companies, not-for-profit organizations, and certain smaller reporting companies applying the credit losses (CECL), the revised effective for fiscal years beginning after December 15, 2022. In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, Income Taxes, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. ASU 2019-12 is effective for fiscal years beginning after December 15, 2021. Most amendments within the standard are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. There is no significant impact from adopting ASU 2019-12 on the Company’s financial condition, results of operations, and cash flows. In April 2021, The FASB issued ASU 2021-04 to codify the final consensus reached by the Emerging Issues Task Force (EITF) on how an issuer should account for modifications made to equity-classified written call options (hereafter referred to as a warrant to purchase the issuer’s common stock). The guidance in the ASU requires the issuer to treat a modification of an equity-classified warrant that does not cause the warrant to become liability-classified as an exchange of the original warrant for a new warrant. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the warrant or as termination of the original warrant and issuance of a new warrant. The Company adopted this guidance for the fiscal year beginning April 1, 2022. There is no significant impact from adopting ASU 2021-04 on the Company’s financial condition, results of operations, and cash flows.

4. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20221231_zHNYMv7baXNg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20220331_zsg6wh9uas95" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As at December 31, 2022 $</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As at March 31, 2022 $</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_405_ecustom--AccountsPayableAndDeferredRevenueCurrent_iI_maAPAALzumA_zb8ZJiQ0UeX4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 63%; text-align: left">Accounts payable and deferred revenue</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right">2,383,657</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">1,159,477</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AccruedLiabilitiesCurrent_iI_maAPAALzumA_zaLVv0ZBC2Mk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Accrued liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,106,769</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,436,270</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iTI_mtAPAALzumA_zwrMgkoPAS8l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Accounts payable and accrued liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,490,426</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,595,747</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> Accounts payable as at December 31, 2022 included $203,525 current account with a shareholder and executive (March 31, 2022: $2,851 due to shareholder and executive) of the Company, primarily as a result of that individual’s role as an employee. These amounts are unsecured, non-interest bearing and payable on demand.

SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20221231_zHNYMv7baXNg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20220331_zsg6wh9uas95" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As at December 31, 2022 $</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As at March 31, 2022 $</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_405_ecustom--AccountsPayableAndDeferredRevenueCurrent_iI_maAPAALzumA_zb8ZJiQ0UeX4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 63%; text-align: left">Accounts payable and deferred revenue</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right">2,383,657</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">1,159,477</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AccruedLiabilitiesCurrent_iI_maAPAALzumA_zaLVv0ZBC2Mk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Accrued liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,106,769</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,436,270</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iTI_mtAPAALzumA_zwrMgkoPAS8l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Accounts payable and accrued liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,490,426</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,595,747</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table>

2383657 1159477

1106769

1436270

3490426

2595747

203525

2851

5. CONVERTIBLE NOTES AND SHORT-TERM LOANS SCHEDULE OF CONVERTIBLE NOTES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" id="xdx_490_20220401__20221231_znhG8TdWnkaf" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Total $</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_406_ecustom--ConvertibleNotesShortTermLoansAndPromissoryNotes_iS_zBzQfOTJBHlk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 82%; font-weight: bold; font-style: italic">Balance at March 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">1,540,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ConversionOfStockAmountIssued1_iN_di_zYk4VpXqFoa9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Conversion to common shares (Note 9)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(555,600</td><td style="text-align: left">)</td></tr> <tr id="xdx_400_ecustom--RedemptionOfConvertibleNotes_iN_di_zJ9k1XsqoEQc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Redemption of convertible notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(53,250</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_ecustom--ConvertibleNoteModification_zWtdbXu01OOf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Convertible note extinguishment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(500,000</td><td style="text-align: left">) </td></tr> <tr id="xdx_403_ecustom--NewIssuanceOfConvertibleNoteNetOfDiscounts_zB8DsdDRpUIk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">New issuance of convertible note, net of discounts</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">556,864</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--NewIssuanceOfShorttermLoanAndPromissoryNotesNetOfDiscounts_z4G0JTNvzVb8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">New issuance of short-term loan and promissory notes, net of discounts</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,156,480</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--RepaymentsOfDebt_iN_di_zCeNrO5mcELl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Repayment of short-term loans</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(20,264</td><td style="text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--AmortizationOfDebtDiscountPremium_zkIRxTEHlLSf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Amortization of discounts</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,407</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--ConvertibleNotesShortTermLoansAndPromissoryNotes_iE_zPhhmp6BaED5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic">Balance at December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,125,637</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> Interest expense on the above debt instruments was $69,930 and $126,574 for the three and nine months ended December 31, 2022, respectively, and $77,791 and $828,769 for the three and nine months ended December 31, 2021, respectively. Series A Convertible Promissory Notes: During the year ended March 31, 2021, the Company issued $11,275,500 (face value) in two series of convertible promissory notes (the “Series A Notes”) sold under subscription agreements to accredited investors. The Notes mature one year from the final closing date of the offering and accrue interest at 12% per annum. For first series of Series A Notes, commencing six months following the Issuance Date, and at any time thereafter (provided the Holder has not received notice of the Company’s intent to prepay the note), at the sole election of the Holder, any amount of the outstanding principal and accrued interest of this note (the “Outstanding Balance”) could be converted into that number of shares of Common Stock equal to: (i) the Outstanding Balance divided by (ii) 75% of the volume weighted average price of the Common Stock for the 5 trading days prior to the Conversion Date (the conversion price). BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022 (Unaudited) (Expressed in US dollars) For the first series of Series A Notes, the notes would automatically convert into common stock (in each case, subject to the trading volume of the Company’s common stock being a minimum of $500,000 for each trading day in the 20 consecutive trading days immediately preceding the conversion date), upon the earlier to occur of (i) the Company’s common stock being listed on a national securities exchange, in which event the conversion price would be equal to 75% of the volume weighted average price of the common stock for the 20 trading days prior to the conversion date, or (ii) upon the closing of the Company’s next equity round of financing for gross proceeds of greater than $5,000,000, in which event the conversion price would be equal to 75% of the price per share of the common stock (or of the conversion price in the event of the sale of securities convertible into common stock) sold in such financing. The Company could, at its discretion redeem the notes for 115% of their face value plus accrued interest. For second series of Series A Notes, the notes could be converted into shares of common stock, at the option of the holder, commencing six months from issuance, at a conversion price equal to the lower of $4.00 per share or 75% of the volume weighted average price of the common stock for the five trading days prior to the conversion date For the second series of Series A Notes, the notes would automatically convert into common stock (in each case, subject to the trading volume of the Company’s common stock being a minimum of $500,000 for each trading day in the 20 consecutive trading days immediately preceding the conversion date), upon the earlier to occur of (i) the Company’s common stock being listed on a national securities exchange, in which event the conversion price would be equal to the lower of $4.00 per share or 75% of the volume weighted average price of the common stock for the 20 trading days prior to the conversion date, or (ii) upon the closing of the Company’s next equity round of financing for gross proceeds of greater than $5,000,000, in which event the conversion price would be equal to the lower of $4.00 per share or 75% of the price per share of the common stock (or of the conversion price in the event of the sale of securities convertible into common stock) sold in such financing. The Company could, at its discretion redeem the notes for 115% of their face value plus accrued interest. <span id="xdx_90A_ecustom--PlacementAgentFeesDescription_c20210401__20220331__us-gaap--DebtInstrumentAxis__custom--SeriesANotesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znzkADynoX44" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company was obligated to issue warrants that accompany the convertible notes and provide 50% warrant coverage. The warrants have a 3-year term from date of issuance and an exercise price that is 120% of the 20-day volume weighted average price of the Company’s common shares at the time final closing. <span id="xdx_900_ecustom--PlacementAgentFeesDescription_c20210401__20220331__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--DebtInstrumentAxis__custom--SeriesANotesMember_zjdz4u1uxHZf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company was obligated to pay the placement agent of the first series of Series A Notes a 12% cash fee for $8,925,550 (face value) of the notes and 2.5% cash fee and other sundry expenses for the remaining $2,350,000 (face value) of the notes. Net proceeds to the Company from Series A Notes issuance up to March 31, 2021 amounted to $10,135,690 after payment of the relevant financing related fees. <span id="xdx_900_ecustom--PlacementAgentFeesDescription_c20210401__20220331__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQDYaT3yg4t5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company was also obligated to issue warrants to the placement agent that have a 10-year term and cover 12% of funds raised for $8,925,550 (face value) of the notes (first series) and 2.5% of funds raised for the remaining $2,350,000 (face value) of notes (second series), with an exercise price that is 120% of the 20-day volume weighted average price of the Company’s common shares at the time final closing. On final closing, which occurred on January 8, 2021, the warrants’ exercise price was struck at $1.06 per share. Prior to January 8, 2021 (final closing date), the Company determined that the conversion and redemption features, investor warrants and placement agent warrants contained in those Notes represented a single compound derivative liability that meets the requirements for liability classification under ASC 815. The Company accounted for these obligations by determining the fair value of the related derivative liabilities associated with the embedded conversion and redemption features, as well as investor warrants and placement agent warrants. BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022 (Unaudited) (Expressed in US dollars) Subsequently, the exercise price of all warrants was concluded and locked to $1.06 as of January 8, 2021. Since the exercise price was no longer a variable, the Company concluded that the noteholder and placement agent warrants should no longer be accounted for as a derivative liability in accordance with ASC 815 guidelines related to equity indexation and classification. The derivative liabilities related to those warrants were therefore marked to market as of January 8, 2021 and then transferred to equity (collectively, “End of warrants derivative treatment”). Therefore, the remaining derivative liabilities only related to the conversion and redemption features of the convertible notes. For the Series A Notes, The Company recognized debt issuance costs in the amount of $2,301,854 and treated these as a deduction from the convertible note liabilities directly, as a contra-liability, and amortized the debt issuance cost over the term of the Notes. The Company also recognized initial debt discount in the amount of $8,088,003 and accreted the interest over the remaining lives of those Notes. The debt issuance costs were fully amortized as of March 31, 2022. As at March 31, 2022, $700,000 of Series A Notes remained unconverted and outstanding, which was equal to the face value of the relevant convertible notes. There was no conversion of Series A Notes during the nine months ended December 31, 2022. On December 30, 2022, the Company exchanged $500,000 of Series A Notes along with its outstanding interest accrual of $121,500 into a new convertible note with the same note holder. The new convertible note has principal of $621,500, stated interest rate of 12%, as well as option to convert outstanding principal and accrued interest at the conversion price, calculated at 75% multiplied by the average of the three lowest closing prices during the previous ten trading days prior to the receipt of the conversion notice. The new convertible note matures on December 30, 2023. The Company had concluded that this exchange transaction is an extinguishment of the original convertible note. Therefore, the Company recorded the new convertible note at fair value, which was its face value of $621,500 net of a discount of $64,636. The difference between the fair value of the original convertible note immediately prior to the extinguishment and the fair value of the new convertible note is $64,636. This amount was recorded as a gain upon debt extinguishment and was included in other income on the income statement. In addition, the Company had assessed fair value of the derivative liability associated with the conversion option on the original note immediately before the modification, as well as the fair value of the derivative liability associated with the new convertible note. The difference $14,083 was recognized as other expense [Note 8]. As of December 31, 2022, the Company recorded $50,400 of interest accruals for the Series A Notes. In connection with the foregoing, the Company relied upon the exemption from registration provided by Section 4(a)(2) under the Securities Act of 1933, as amended, for transactions not involving a public offering. Series B Convertible Notes In addition, during the year ended March 31, 2021, the Company also issued $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20210331__us-gaap--DebtInstrumentAxis__custom--SeriesBNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorsMember_zjoy8cbEy7J8">1,312,500 (face value) of convertible promissory notes (“Series B Notes”) to various accredited investors. Commencing six months following the issuance date, and at any time thereafter, subject to the Company’s Conversion Buyout clause, at the sole election of the holder, any amount of the outstanding principal and accrued interest of the note (the “outstanding balance”) could be converted into that number of shares of Common Stock equal to: (i) the outstanding balance divided by (ii) the Conversion Price. Partial conversions of the note shall have the effect of lowering the outstanding principal amount of the note. The holder may exercise such conversion right by providing written notice to the Company of such exercise in a form reasonably acceptable to the Company (a “conversion notice”). Conversion price means (subject in all cases to proportionate adjustment for stock splits, stock dividends, and similar transactions), seventy-five percent (75%) multiplied by the average of the three (3) lowest closing prices during the previous ten (10) trading days prior to the receipt of the conversion notice. <span id="xdx_908_eus-gaap--DebtConversionDescription_c20220401__20221231__us-gaap--DebtInstrumentAxis__custom--SeriesBNotesMember_z8kWmH2ZzCA4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Series B Notes will automatically convert into common stock upon a merger, consolidation, exchange of shares, recapitalization, reorganization, as a result of which the Company’s common stock shall be changed into another class or classes of stock of the Company or another entity, or in the case of the sale of all or substantially all of the assets of the Company other than a complete liquidation of the Company. Within the first 180 days after the issuance date, the Company may, at its discretion redeem the notes for 115% of their face value plus accrued interest. The Company is obligated to issue warrants that accompany the convertible notes and provide 50% warrant coverage. The warrants have a <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--DebtInstrumentAxis__custom--SeriesBNotesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQlq30u7KE91">3-year term from date of issuance and an exercise price that is $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--DebtInstrumentAxis__custom--SeriesBNotesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z835LYn98FL8">1.06 per share for <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20221231__us-gaap--DebtInstrumentAxis__custom--SeriesBNotesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkQIYcHVdioc">100,000 warrant shares and $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220331__us-gaap--DebtInstrumentAxis__custom--SeriesBNotesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqMHtGFXc0k3">1.5 per share for <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20220331__us-gaap--DebtInstrumentAxis__custom--SeriesBNotesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7K8SHKfg7bf">212,500 warrant shares. BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022 (Unaudited) (Expressed in US dollars) Net proceeds to the Company from convertible note issuances to March 31, 2021 amounted to $1,240,000 after the original issuance discount as well as payment of the financing related fees. The Company determined that the conversion and redemption features contained in the Series B Notes represented a single compound derivative liability that meets the requirements for liability classification under ASC 815. The Company accounted for these obligations by determining the fair value of the related derivative liability associated with the embedded conversion and redemption features. The Company recognized debt issuance costs in the amount of $10,000 and treated these as a deduction from the convertible note liabilities directly, as a contra-liability, and amortized the debt issuance cost over the term of the Series B Notes. The Company recognized initial debt discount in the amount of $1,312,500 and accreted the interest over the remaining lives of those notes. The debt issuance costs were fully amortized as of March 31, 2022. As at March 31, 2022, $840,000 of Series B Notes remained unconverted and outstanding, which was equal to the face value of the relevant convertible notes. During the three and nine months ended December 31, 2022, $153,600 and $555,600 (face value) of Series B Notes were converted into 238,846 and 746,957 common shares (Note 9 d). During the three and nine months ended December 31, 2022, $53,250 (face value) of Series B Notes were redeemed by cash payment of $61,238. The redemption price was determined in accordance to the Series B note agreement, where the Company has an option to redeem the note at 115% of its principal value instead of converting the note upon receipt of a conversion notice. The difference between the redemption cash payment and the book value of the note redeemed, including the derivative liability associated to the note, was $9,991, and was recognized as a gain upon convertible note repayment. As of December 31, 2022, the Company recorded accrued interest in the amount of $82,509 related to the Series B Notes. In connection with the foregoing, the Company relied upon the exemption from registration provided by Section 4(a)(2) under the Securities Act of 1933, as amended, for transactions not involving a public offering. In total, as at December 31, 2022, the Company had issued $200,000 and $231,150 for Series A and Series B notes, respectively, that remained outstanding beyond their contractual maturity date. These continued to accrue interest, and no repayment demands were received from noteholders, notwithstanding the fact that these noteholders have continued to convert portions of these notes subsequently, and it is management’s expectation that all of these notes will eventually convert. In connection with the foregoing, the Company relied upon the exemption from registration provided by Section 4(a)(2) under the Securities Act of 1933, as amended, for transactions not involving a public offering. Other Short-term loans and Promissory Notes During the three months ended December 31, 2022, the Company entered into a short-term bridge loan agreement with a collateralized merchant finance company that advanced gross proceeds of $<span id="xdx_90A_eus-gaap--ProceedsFromShortTermDebt_c20221208__20221208__us-gaap--DebtInstrumentAxis__custom--ShortTermSecuritizedBridgeLoanMember__dei--LegalEntityAxis__custom--CFGMerchantSolutionsLLCMember_zhPdaI6vx1md">400,000, prior to the deduction of issuance costs in the amount of $<span id="xdx_90D_eus-gaap--DeferredFinanceCostsNet_iI_c20221208__us-gaap--DebtInstrumentAxis__custom--ShortTermSecuritizedBridgeLoanMember__dei--LegalEntityAxis__custom--CFGMerchantSolutionsLLCMember_zzO588EBCIae">9,999. The issuance costs were recognized as a debt discount and amortized via the effective interest method. The term of the finance agreement is <span id="xdx_904_eus-gaap--DebtInstrumentTerm_dtW_c20221208__20221208__us-gaap--DebtInstrumentAxis__custom--ShortTermSecuritizedBridgeLoanMember__dei--LegalEntityAxis__custom--CFGMerchantSolutionsLLCMember_zoXnGIcT9Ur9">40 weeks. The Company is required to make weekly payments of $<span id="xdx_90B_eus-gaap--DebtInstrumentPeriodicPayment_c20221214__20221216__us-gaap--DebtInstrumentAxis__custom--ShortTermSecuritizedBridgeLoanMember__dei--LegalEntityAxis__custom--CFGMerchantSolutionsLLCMember_zn4AhNNeAbY9">13,995 ($<span id="xdx_901_eus-gaap--DebtInstrumentCarryingAmount_iI_c20221216__us-gaap--DebtInstrumentAxis__custom--ShortTermSecuritizedBridgeLoanMember__dei--LegalEntityAxis__custom--CFGMerchantSolutionsLLCMember_zgWDOhlBdq56">560,000 in the aggregate). As of December 31, 2022, the amount of principal outstanding was $<span id="xdx_90C_eus-gaap--DebtInstrumentCarryingAmount_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--ShortTermSecuritizedBridgeLoanMember__dei--LegalEntityAxis__custom--CFGMerchantSolutionsLLCMember_z7drI7lr6Bwf">380,500. The remaining unamortized issuance cost discount was $<span id="xdx_900_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--ShortTermSecuritizedBridgeLoanMember__dei--LegalEntityAxis__custom--CFGMerchantSolutionsLLCMember_zQzCsHp33wj2">9,392. The Company has an option to repay the loan earlier to receive a discount on total repayment. If the Company repays within 30 days, the total repayment is $512,000. If the Company repays within 60 days, the total repayment is $520,000. If the Company repays within 90 days, the total repayment is $528,000. During the three months ended December 31, 2022, the Company also entered into a short term collateralized bridge loan agreement with a finance company that advanced gross proceeds of $<span id="xdx_903_eus-gaap--ProceedsFromShortTermDebt_c20221221__20221221__us-gaap--DebtInstrumentAxis__custom--ShortTermSecuritizedBridgeLoanMember__dei--LegalEntityAxis__custom--BalancedManagementLLCMember_zRsCShZXV301">800,000, prior to the deduction of issuance costs in the amount of $<span id="xdx_90E_eus-gaap--DeferredFinanceCostsNet_iI_c20221221__us-gaap--DebtInstrumentAxis__custom--ShortTermSecuritizedBridgeLoanMember__dei--LegalEntityAxis__custom--BalancedManagementLLCMember_z1WCvSD3HCX8">32,000. The issuance costs were recognized as a debt discount and amortized via the effective interest method. The term of this second agreement is <span id="xdx_909_eus-gaap--DebtInstrumentTerm_dtW_c20221221__20221221__us-gaap--DebtInstrumentAxis__custom--ShortTermSecuritizedBridgeLoanMember__dei--LegalEntityAxis__custom--BalancedManagementLLCMember_zuug3yeChYyj">40 weeks. The Company is required to make weekly payments of $<span id="xdx_902_eus-gaap--DebtInstrumentPeriodicPayment_c20221230__20221230__us-gaap--DebtInstrumentAxis__custom--ShortTermSecuritizedBridgeLoanMember__dei--LegalEntityAxis__custom--BalancedManagementLLCMember_zJuFsmCs99k8">29,556 ($<span id="xdx_902_eus-gaap--DebtInstrumentPeriodicPayment_c20221230__20221230__us-gaap--DebtInstrumentAxis__custom--ShortTermSecuritizedBridgeLoanMember__dei--LegalEntityAxis__custom--BalancedManagementLLCMember__us-gaap--AwardDateAxis__custom--FirstFourWeeksMember_zsd2rMOpudp8">14,999 for the first four weeks, and $<span id="xdx_900_eus-gaap--DebtInstrumentCarryingAmount_iI_c20221230__us-gaap--DebtInstrumentAxis__custom--ShortTermSecuritizedBridgeLoanMember__dei--LegalEntityAxis__custom--CFGMerchantSolutionsLLCMember_zj3GUOYLGQWl">1,120,000 in the aggregate). As of December 31, 2022, the amount of principal and interest outstanding under this agreement was $<span id="xdx_906_eus-gaap--DebtInstrumentCarryingAmount_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--ShortTermSecuritizedBridgeLoanMember__dei--LegalEntityAxis__custom--CFGMerchantSolutionsLLCMember__us-gaap--TypeOfArrangementAxis__custom--BalancedManagementAgreementMember_zebL5LVggR5f">799,236 and the remaining unamortized issuance cost discount was $<span id="xdx_90A_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--ShortTermSecuritizedBridgeLoanMember__dei--LegalEntityAxis__custom--CFGMerchantSolutionsLLCMember__us-gaap--TypeOfArrangementAxis__custom--BalancedManagementAgreementMember_zsF9Ul9WdwAl">31,200. The Company has an option to repay the loan earlier and receive a discount on total repayment. The total repayment amount becomes $920,000 if repaid within 30 days, $944,000 if repaid within 60 days, $968,000 if repaid within 90 days, $1,000,000 if repaid within 120 days, and $1,088,000 if repaid within 150 days. In December 2022, the Company entered into a promissory note agreement with an individual investor that resulted in gross proceeds of $<span id="xdx_90C_eus-gaap--DebtInstrumentCarryingAmount_iI_c20221215__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteAgreementMember__dei--LegalEntityAxis__custom--IndividualInvestorMember_zMPA6DF9qrk8">600,000 (the “Principal Amount”). The note has a fixed rate of interest at <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateDuringPeriod_uPure_c20221214__20221215__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteAgreementMember__dei--LegalEntityAxis__custom--IndividualInvestorMember_zXYo4uvCuZu2">25% per annum payable monthly on the first day of every month. This promissory note matures on December 15, 2023, when the Principal Amount is due. The note has various default provisions which would, if triggered, result in the acceleration of the Principal Amount plus any accrued and unpaid interest. The note also has a <span id="xdx_90D_ecustom--EarlyPaymentPenaltyProvisionPercentage_dp_uPure_c20221214__20221215__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteAgreementMember__dei--LegalEntityAxis__custom--IndividualInvestorMember_ziQ6n5tBaiN8">3% early payment penalty provision. As of December 31, 2022, the amount of principal outstanding on the note was $<span id="xdx_90E_eus-gaap--DebtInstrumentCarryingAmount_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteAgreementMember__dei--LegalEntityAxis__custom--IndividualInvestorMember_zmd9YIV296xh">600,000, and accrued interest outstanding on the note was $<span id="xdx_904_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteAgreementMember__dei--LegalEntityAxis__custom--IndividualInvestorMember_zqdQoijRueA6">6,575. Also in December 2022, the Company received a short-term loan in the amount of $150,000 from an individual investor. There was no interest or issuance cost associated with the latter loan, which was repaid in January 2023. BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022 (Unaudited) (Expressed in US dollars) On December 30, 2022, the Company extinguished 306,604 warrants (Note 9f) that were originally issued to Series A Convertible Note holders, and replaced these warrants with a new promissory note issued to the same warrant holder. The new promissory note has principal balance of $270,000, stated interest of zero, and matures on June 30, 2023. The Company is obligated to repay 50% of the principal balance on March 31, 2023, and the rest of the promissory notes on the maturity date. The fair value of this new promissory note was $248,479 as of the issuance date, which was calculated using a discount rate that was comparable to other loan issuance at the same time as well as the market bond rates at the time of the promissory note issuance. The difference between the fair value of the new note and its principal balance was $21,521, and was recognized as a discount, and will be amortized via effective interest rate method. The Company compared the fair value of the extinguished warrants immediately prior to extinguishment against the fair value of the new promissory note issued. The difference between these fair values is $176,711, and was recognized as other expense on the income statement. As of December 31, 2022, the amount of principal outstanding on the new note was $270,000, and the remaining unamortized discount was $21,521.

SCHEDULE OF CONVERTIBLE NOTES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" id="xdx_490_20220401__20221231_znhG8TdWnkaf" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Total $</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_406_ecustom--ConvertibleNotesShortTermLoansAndPromissoryNotes_iS_zBzQfOTJBHlk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 82%; font-weight: bold; font-style: italic">Balance at March 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">1,540,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ConversionOfStockAmountIssued1_iN_di_zYk4VpXqFoa9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Conversion to common shares (Note 9)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(555,600</td><td style="text-align: left">)</td></tr> <tr id="xdx_400_ecustom--RedemptionOfConvertibleNotes_iN_di_zJ9k1XsqoEQc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Redemption of convertible notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(53,250</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_ecustom--ConvertibleNoteModification_zWtdbXu01OOf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Convertible note extinguishment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(500,000</td><td style="text-align: left">) </td></tr> <tr id="xdx_403_ecustom--NewIssuanceOfConvertibleNoteNetOfDiscounts_zB8DsdDRpUIk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">New issuance of convertible note, net of discounts</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">556,864</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--NewIssuanceOfShorttermLoanAndPromissoryNotesNetOfDiscounts_z4G0JTNvzVb8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">New issuance of short-term loan and promissory notes, net of discounts</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,156,480</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--RepaymentsOfDebt_iN_di_zCeNrO5mcELl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Repayment of short-term loans</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(20,264</td><td style="text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--AmortizationOfDebtDiscountPremium_zkIRxTEHlLSf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Amortization of discounts</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,407</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--ConvertibleNotesShortTermLoansAndPromissoryNotes_iE_zPhhmp6BaED5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic">Balance at December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,125,637</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table>

1540000

555600

53250 -500000 556864 2156480

20264

1407

3125637

69930

77791

828769

11275500

0.12

the notes would automatically convert into common stock (in each case, subject to the trading volume of the Company’s common stock being a minimum of $500,000 for each trading day in the 20 consecutive trading days immediately preceding the conversion date), upon the earlier to occur of (i) the Company’s common stock being listed on a national securities exchange, in which event the conversion price would be equal to 75% of the volume weighted average price of the common stock for the 20 trading days prior to the conversion date, or (ii) upon the closing of the Company’s next equity round of financing for gross proceeds of greater than $5,000,000, in which event the conversion price would be equal to 75% of the price per share of the common stock (or of the conversion price in the event of the sale of securities convertible into common stock) sold in such financing. The Company could, at its discretion redeem the notes for 115% of their face value plus accrued interest.

4.00

the notes would automatically convert into common stock (in each case, subject to the trading volume of the Company’s common stock being a minimum of $500,000 for each trading day in the 20 consecutive trading days immediately preceding the conversion date), upon the earlier to occur of (i) the Company’s common stock being listed on a national securities exchange, in which event the conversion price would be equal to the lower of $4.00 per share or 75% of the volume weighted average price of the common stock for the 20 trading days prior to the conversion date, or (ii) upon the closing of the Company’s next equity round of financing for gross proceeds of greater than $5,000,000, in which event the conversion price would be equal to the lower of $4.00 per share or 75% of the price per share of the common stock (or of the conversion price in the event of the sale of securities convertible into common stock) sold in such financing. The Company could, at its discretion redeem the notes for 115% of their face value plus accrued interest.

The Company was obligated to issue warrants that accompany the convertible notes and provide 50% warrant coverage. The warrants have a 3-year term from date of issuance and an exercise price that is 120% of the 20-day volume weighted average price of the Company’s common shares at the time final closing. The Company was obligated to pay the placement agent of the first series of Series A Notes a 12% cash fee for $8,925,550 (face value) of the notes and 2.5% cash fee and other sundry expenses for the remaining $2,350,000 (face value) of the notes.

10135690

The Company was also obligated to issue warrants to the placement agent that have a 10-year term and cover 12% of funds raised for $8,925,550 (face value) of the notes (first series) and 2.5% of funds raised for the remaining $2,350,000 (face value) of notes (second series), with an exercise price that is 120% of the 20-day volume weighted average price of the Company’s common shares at the time final closing. On final closing, which occurred on January 8, 2021, the warrants’ exercise price was struck at $1.06 per share.

1.06

2301854

8088003

700000

500000

121500

621500

0.12

0.75

621500

64636

14083

50400

1312500

The holder may exercise such conversion right by providing written notice to the Company of such exercise in a form reasonably acceptable to the Company (a “conversion notice”). Conversion price means (subject in all cases to proportionate adjustment for stock splits, stock dividends, and similar transactions), seventy-five percent (75%) multiplied by the average of the three (3) lowest closing prices during the previous ten (10) trading days prior to the receipt of the conversion notice.

The Series B Notes will automatically convert into common stock upon a merger, consolidation, exchange of shares, recapitalization, reorganization, as a result of which the Company’s common stock shall be changed into another class or classes of stock of the Company or another entity, or in the case of the sale of all or substantially all of the assets of the Company other than a complete liquidation of the Company. Within the first 180 days after the issuance date, the Company may, at its discretion redeem the notes for 115% of their face value plus accrued interest. The Company is obligated to issue warrants that accompany the convertible notes and provide 50% warrant coverage.

P3Y

1.06

100000

1.5

212500

1240000

10000

1312500

840000

153600

555600

238846

53250

61238

The redemption price was determined in accordance to the Series B note agreement, where the Company has an option to redeem the note at 115% of its principal value instead of converting the note upon receipt of a conversion notice. The difference between the redemption cash payment and the book value of the note redeemed, including the derivative liability associated to the note

9991

82509

200000

231150

400000

9999

P280D

13995

560000

380500

9392

512000

520000

528000

800000

32000

P280D

29556

14999

1120000

799236

31200

920000

944000

968000

1000000

1088000

600000

0.25

0.03

600000

6575

150000

306604

270000

0.50

248479

21521

176711

270000

21521

6. TERM LOAN AND CREDIT AGREEMENT Term Loan On December 21, 2021, the Company entered into a Credit Agreement (“Credit Agreement”) with SWK Funding LLC (“Lender’), wherein the Company has borrowed $12,000,000, with a maturity date of December 21, 2026. The principal will accrue interest at the LIBOR Rate plus 10.5% per annum (subject to adjustment as set forth in the Credit Agreement). Interest payments are due on each February, May, August and November commencing February 15, 2022. Pursuant to the Credit Agreement, the Company will be required to make interest only payments for the first 24 months (which may be extended to 36 months under prescribed circumstances), after which payments will include principal amortization that accommodates a 40% balloon principal payment at maturity. Prepayment of amounts owing under the Credit Agreement are allowed under prescribed circumstances. Pursuant to the Credit Agreement the Company is subject to an Origination Fee in the amount of $120,000. Upon Termination of the Credit Agreement, the Company shall pay an Exit Fee of $600,000.  As part of the loan transaction, the Company paid legal and professional costs directly in connection to the debt financing in the amount of $50,000 in cash. Total costs directly in connection to the debt financing in the amount of $193,437 (professional fee $48,484; lender’s origination fee, due diligence fee, and other expenses in the amount of $144,953) was deduced from the gross proceeds in the amount of $12,000,000. BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022 (Unaudited) (Expressed in US dollars) The Company also repaid $1,574,068 of existing short-term loan and promissory notes and relevant accrued interests by using the proceeds from the loan. Total costs directly in connection to the loan and fair value of warrants was in the amount of $1,042,149. And such costs were accounted as debt discount, and amortized using the effective interest method. The amortization of such debt discount was included in the accretion and amortization expenses. For the three and nine months ended December 31, 2022, the amortization of debt discount expense was $51,061 and $151,970 respectively. Total interest expense on the term loan for the three and nine months ended December 31, 2022 was $335,242 and $1,054,166, respectively (three and nine months ended December 31, 2022: $38,333 and $38,333). On December 31, 2022, the Company was not in compliance with certain covenants of the term loan, for which it sought and received relief from the term loan lender. The Company and Lender also entered into a Guarantee and Collateral Agreement (“Collateral Agreement”) wherein the Company agreed to secure the Credit Agreement with all of the Company’s assets. The Company and Lender also entered into an Intellectual Property Security Agreement dated December 21, 2021 (the “IP Security Agreement”) wherein the Credit Agreement is also secured by the Company’s right title and interest in the Company’s Intellectual Property. In connection with the Credit Agreement, the Company issued 57,536 warrants to the Lender, which were fair-valued at $198,713 (Note 9). The warrants are accounted as a deduction from liability as well as a credit into additional paid-in capital, and amortized using the effective interest method.

12000000

2026-12-21

0.105

2022-02-15

Pursuant to the Credit Agreement, the Company will be required to make interest only payments for the first 24 months (which may be extended to 36 months under prescribed circumstances), after which payments will include principal amortization that accommodates a 40% balloon principal payment at maturity. Prepayment of amounts owing under the Credit Agreement are allowed under prescribed circumstances

120000 600000

50000

193437

48484

144953

12000000

1574068

1042149

51061

151970

335242

1054166

38333

57536

198713

7. FEDERALLY GUARANTEED LOANS Economic Injury Disaster Loan (“EIDL”) In April 2020, the Company received $370,900 from the U.S. Small Business Administration (SBA) under the captioned program. The loan has a term of <span id="xdx_907_eus-gaap--DebtInstrumentTerm_c20200401__20200430__us-gaap--DebtInstrumentAxis__custom--EconomicInjuryDisasterLoanMember_zXMFuk3aik53" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30 years <span id="xdx_903_eus-gaap--DebtInstrumentDescription_c20200401__20200430__us-gaap--DebtInstrumentAxis__custom--EconomicInjuryDisasterLoanMember_zZJIeh8UsVRl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and an interest rate of <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20200430__us-gaap--DebtInstrumentAxis__custom--EconomicInjuryDisasterLoanMember_zgO54TncTjWl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.75% per annum, without the requirement for payment in its first 12 months. The Company may prepay the loan without penalty at will. In May 2021, the Company received an additional $499,900 from the SBA under the same terms. As at December 31, 2022, the Company recorded accrued interest of $60,520 for the EIDL loan (December 31, 2021: $36,181). Interest expense on the above loan was $8,231 and $24,602 for the three and nine months ended December 31, 2022, respectively, and $8,231 and $36,181 for the three and nine months ended December 31, 2021, respectively. Payment Protection Program (“PPP”) Loan In May 2020, Biotricity received loan proceeds of $1,200,000 (the “PPP Loan”) under the Paycheck Protection Program established by the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”) administered by the U.S. Small Business Administration (“SBA”). The Company met the criteria for the loan forgiveness and applied for the loan forgiveness in March 2021. For the year ended March 31, 2021, the Company recognized the loan forgiveness as a reduction to payroll expense in the amount of $1,156,453 and a reduction to the rent expense of $43,547. The loan forgiveness was granted by the SBA in May 2021. As at December 31, 2022, the balance of outstanding PPP loan is NIL (March 31, 2022: NIL).

370900

P30Y

and an interest rate of

0.0375

499900

8231

24602

8231

36181

1200000

1156453

43547

8. DERIVATIVE LIABILITIES On December 19, 2019 and January 9, 2020, the Company issued 7,830 Series A preferred shares; 6,000 of these were issued for cash proceeds of $6,000,000 and 1,830 of these were issued on conversion of $1,830,000 of promissory notes that had previously been issued for cash proceeds in October 2019. BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022 (Unaudited) (Expressed in US dollars) On May 22, 2020, another 215 Series A preferred shares were issued as a result of a combined transaction that included the conversion of $100,000 in promissory notes and $15,000 in accrued interest for 115 preferred shares, as well as a purchase of 100 preferred shares for cash proceeds of $100,000. During the three months ended September 30, 2021, an additional 100 Series A preferred shares were issued for cash proceeds of $100,000 (Note 9 d). During the three months ended December 31, 2021, the Company redeemed $230,000 preferred shares through cash. The total amount of the preferred shares redeemed and derivative liabilities derecognized was $225,919. The difference of redemption value of $230,000 and the carrying value of preferred shares on the day of redemption was $4,081 was recognized as a deemed dividend distribution. In addition, during the three months ended December 31, 2021, the Company converted $715,000 preferred shares into 288,756 common shares. The difference between the total amount of the preferred shares converted, derivative liabilities derecognized and unpaid interests at the time of conversion ($1,076,513), and the fair value of the common shares converted ($1,226,406) was $149,893 and was recognized as deemed dividend distribution. During the three months ended June 30, 2022, the Company redeemed $328,904 preferred shares through cash. The total amount of the preferred shares redeemed and derivative liabilities derecognized was $296,032. The difference of redemption value of $328,904 and the carrying value of preferred shares on the day of redemption was $32,872 and was recognized as a deemed dividend distribution During the three months ended September 30, 2022, the Company redeemed $69,852 preferred shares through cash. The total amount of the preferred shares redeemed and derivative liabilities derecognized was $65,062. The difference of redemption value of $69,852 and the carrying value of preferred shares on the day of redemption was $4,790 and was recognized as a deemed dividend distribution. During the three months ended December 31, 2022, the Company redeemed $496,800 preferred shares through cash. The total amount of the preferred shares redeemed and derivative liabilities derecognized was $469,116. The difference of redemption value of $496,800 and the carrying value of preferred shares on the day of redemption was $27,684 and was recognized as a deemed dividend distribution. The Company analyzed the compound features of variable conversion and redemption embedded in the preferred shares instrument, for potential derivative accounting treatment on the basis of ASC 820 (Fair Value in Financial Instruments), ASC 815 (Accounting for Derivative Instruments and Hedging Activities), Emerging Issues Task Force (“EITF”) Issue No. 00–19 and EITF 07–05, and determined that the embedded derivatives should be bundled and valued as a single, compound embedded derivative, bifurcated from the underlying equity instrument, treated as a derivative liability, and measured at fair value. SCHEDULE OF DERIVATIVE LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> Fiscal Year 2023 $ </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Fiscal Year 2022 $ </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; width: 64%">Derivative liabilities as at March 31, 2022 and 2021</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20220401__20220630_zEdS4rVcQS06" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Derivative liabilities, beginning balance">352,402</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 14%"><p id="xdx_983_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20210401__20210630_zDySHIp7szhl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right" title="Derivative liabilities, beginning balance">410,042</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Change in fair value of derivatives during the period</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_pp0p0_di_c20220401__20220630_zIqjqqFUv4Wd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in fair value of derivatives during the period">195,521</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"><p id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_pp0p0_di_c20210401__20210630_zA0KiaZcEFgg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right" title="Change in fair value of derivatives during the period">(203,525</td> <td style="font: 10pt Times New Roman, Times, Serif">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Reduction due to preferred shares redeemed</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_ecustom--ReductionDueToPreferredSharesRedeemed_c20220401__20220630_zUvLIhQGPhdb" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Reduction due to preferred shares redeemed">(10,605</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td id="xdx_983_ecustom--ReductionDueToPreferredSharesRedeemed_c20210401__20210630_z8e1fUW5m226" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Reduction due to preferred shares redeemed">-</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: bold 10pt Times New Roman, Times, Serif">Derivative liabilities as at June 30, 2022 and 2021</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20220701__20220930_zQxol0XbJMie" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities, beginning balance">537,318</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_983_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20210701__20210930_zAPUus7IrOOb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities, beginning balance">206,517</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: normal 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: normal 10pt Times New Roman, Times, Serif">New issuance</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20220701__20220930_zAp67zJHpU32" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in fair value new issuance">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20210701__20210930_ziX35yubUQtd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in fair value new issuance">17,084</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Change in fair value of derivatives during the period</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_pp0p0_di_c20220701__20220930_z1HUiDOOJS26" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in fair value of derivatives during the period">168,762</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_pp0p0_di_c20210701__20210930_zGgTlJlMeMHd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in fair value of derivatives during the period">(101,173</td> <td style="font: 10pt Times New Roman, Times, Serif">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Reduction due to preferred shares redeemed</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_ecustom--ReductionDueToPreferredSharesRedeemed_c20220701__20220930_z1GVFk1GJzR5" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Reduction due to preferred shares redeemed">(4,444</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td id="xdx_98B_ecustom--ReductionDueToPreferredSharesRedeemed_c20210701__20210930_zBWENkaXMUyf" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Reduction due to preferred shares redeemed">-</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: bold 10pt Times New Roman, Times, Serif">Derivative liabilities as at September 30, 2022 and 2021</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20221001__20221231_z0wkPVFzyRNb" style="font: normal 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities, beginning balance">701,636</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_981_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20211001__20211231_zdxbrmoUBwrf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities, beginning balance">121,828</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Change in fair value of derivatives during the period</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_pp0p0_di_c20221001__20221231_zlvrHgvi4u8j" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in fair value of derivatives during the period">78,026</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_pp0p0_di_c20211001__20211231_zno84zM2ze3l" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in fair value of derivatives during the period">644,774</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Reduction due to preferred shares redeemed</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_ecustom--ReductionDueToPreferredSharesRedeemed_c20221001__20221231_zoQ5XUmwAgn6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Reduction due to preferred shares redeemed">(37,987</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td id="xdx_988_ecustom--ReductionDueToPreferredSharesRedeemed_c20211001__20211231_zwQ60Umqoal1" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Reduction due to preferred shares redeemed">(479,791</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif">Derivative liabilities as at December 31, 2022 and 2021</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--DerivativeLiabilities_iE_pp0p0_c20221001__20221231_zAOMKtJ8Zi53" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities, ending balance">741,675</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_988_eus-gaap--DerivativeLiabilities_iE_pp0p0_c20211001__20211231_zyIHvo84veg5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities, ending balance">286,811</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> </table> BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022 (Unaudited) (Expressed in US dollars) The lattice methodology was used to value the derivative components, using the following assumptions: SCHEDULE OF DERIVATIVE COMPONENTS VALUATION ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Dividend yield (%)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: right"><span id="xdx_901_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z8xcOpkq5ojc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</td><td style="width: 1%; text-align: left"/></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free rate for term (%)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z0qXDFpOl4b6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.18 – <span id="xdx_90F_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zqtEQMgxPrl5">4.36</td><td style="text-align: left"/></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility (%)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zEYbZB9wXZT1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">92.7 – <span id="xdx_903_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zs5sT301Esvc">93.6</td><td style="text-align: left"/></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Remaining terms (Years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20220401__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zgKAzZ31n5ug" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.00 to <span id="xdx_90A_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20220401__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zTdd6gIsaDy4">2.50</td><td style="text-align: left"/></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Stock price ($ per share)</td><td> </td> <td style="text-align: left"/><td style="text-align: right">0.45 to 0.72</td><td style="text-align: left"> </td></tr> </table> In addition, the Company recorded derivative liabilities related to the conversion and redemption features of the convertible notes, as well as warrants that were issued in connection with the convertible notes, during the year ended March 31, 2021 (Note 5). As the warrant exercise price became final and locked, the derivative liabilities related to those warrants were marked to market and transferred to equity (Note 5). Any noteholder and placement agent warrants that were issued after the finalization of exercise price was accounted for as equity. <p id="xdx_891_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_hus-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z2HMfY0Ms4h6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">SCHEDULE OF DERIVATIVE LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Fiscal Year 2023 $</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">Fiscal Year 2022 $ </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: italic bold 10pt Times New Roman, Times, Serif; width: 64%">Balance at March 31, 2022 and 2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pp0p0_c20220401__20220630__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z3qjILj325ol" style="font: bold 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Derivative liabilities, beginning balance">520,747</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 14%"><p id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pp0p0_c20210401__20210630__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zez1EfdSgTJ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right" title="Derivative liabilities, beginning balance">3,633,856</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Conversion to common shares</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--ConversionOfStockAmountConverted1_pp0p0_c20220401__20220630__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zngWkCZgTkUl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Conversion to common shares">(104,118</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"><p id="xdx_987_eus-gaap--ConversionOfStockAmountConverted1_pp0p0_c20210401__20210630__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zf2XOfGLmRga" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right" title="Conversion to common shares">(403,108</td> <td style="font: 10pt Times New Roman, Times, Serif">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Change in fair value of derivative liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_pp0p0_di_c20220401__20220630__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zKPezGWaCoW" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in fair value of derivatives">2,703</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_pp0p0_di_c20210401__20210630__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zGzN594g15Kf" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in fair value of derivatives">502,508</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: italic bold 10pt Times New Roman, Times, Serif">Balance at June 30, 2022 and 2021</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pp0p0_c20220701__20220930__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zN8n9YfhI0x6" style="font: normal 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities, beginning balance">419,332</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"><p id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pp0p0_c20210701__20210930__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zLJFvU5Pbasd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right" title="Derivative liabilities, beginning balance">3,733,256</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Conversion to common shares</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--ConversionOfStockAmountConverted1_pp0p0_c20220701__20220930__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zXk3cQ725Nhi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Conversion to common shares">(35,274</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"><p id="xdx_98D_eus-gaap--ConversionOfStockAmountConverted1_pp0p0_c20210701__20210930__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zI2W6rgv7V8c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right" title="Conversion to common shares">(2,744,711</td> <td style="font: 10pt Times New Roman, Times, Serif">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Change in fair value of derivative</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_pp0p0_di_c20220701__20220930__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z2jJuut8yile" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in fair value of derivative liabilities">3,280</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_pp0p0_di_c20210701__20210930__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zCUoHyQsc2s1" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in fair value of derivative liabilities">(295,801</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: italic bold 10pt Times New Roman, Times, Serif">Balance at September 30, 2022 and 2021</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pp0p0_c20221001__20221231__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z6OWeeAZtwhl" style="font: normal 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities, beginning balance">387,338</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"><p id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pp0p0_c20211001__20211231__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zbHVVYaK1EF6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right" title="Derivative liabilities, beginning balance">692,744</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Convertible note modification</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_ecustom--ConversionOfStockAmountModification_pp0p0_c20221001__20221231__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zHYF3ilP0rh8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Conversion to modification">14,083 </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Convertible note redemption</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities, beginning balance"><p id="xdx_980_ecustom--ConversionOfStockAmountRedemption_pp0p0_c20221001__20221231__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zcsLCW85CJRe" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Conversion to redemption">(17,979</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Conversion to common shares</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--ConversionOfStockAmountConverted1_pp0p0_c20221001__20221231__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zlrVeFwjlAXc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Conversion to common shares">(53,402</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_989_eus-gaap--ConversionOfStockAmountConverted1_pp0p0_c20211001__20211231__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zeGfr5VpBbhb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Conversion to common shares">(250,738</td> <td style="font: 10pt Times New Roman, Times, Serif">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Change in fair value of derivative</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_pp0p0_di_c20221001__20221231__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zWpgaRhH1yag" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in fair value of derivative liabilities">21,679</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_pp0p0_di_c20211001__20211231__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zCb2J1jr3CTl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right" title="Change in fair value of derivative liabilities">129,999</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: italic bold 10pt Times New Roman, Times, Serif">Balance at December 31, 2022 and 2021</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pp0p0_c20221001__20221231__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zezHKnPXld59" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities, beginning balance">351,719</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"><p id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pp0p0_c20211001__20211231__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zBk1Qy6HeIac" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right" title="Derivative liabilities, beginning balance">572,005</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> </table> <p id="xdx_893_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_hus-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zQq65I4AOd2j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The monte-carlo methodology was used to value the convertible note derivative components, using the following assumptions: SCHEDULE OF WARRANT DERIVATIVE COMPONENTS VALUATION ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">December 2022</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Risk-free rate for term (%)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: right"><span id="xdx_906_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--DebtInstrumentAxis__custom--ConversionAndRedemptionFeaturesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zhy3ypyeYhR1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.74 - <span id="xdx_900_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--ConversionAndRedemptionFeaturesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zIPHuyV3WDtk">4.37</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Volatility (%)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--DebtInstrumentAxis__custom--ConversionAndRedemptionFeaturesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_ztaIqmXw13j2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">90.4 - <span id="xdx_90D_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--ConversionAndRedemptionFeaturesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zpYMSGR44afi">99.6</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Remaining terms (Years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20220401__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--DebtInstrumentAxis__custom--ConversionAndRedemptionFeaturesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zcZTZODpx2Z2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.50 - <span id="xdx_903_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20220401__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--ConversionAndRedemptionFeaturesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z23tfOB1HWP5">0.75</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Stock price ($ per share)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_ecustom--DerivativeStockPrice_iI_pid_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--DebtInstrumentAxis__custom--ConversionAndRedemptionFeaturesMember_zsdRf88BGWB7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.50 - 1.00</td><td style="text-align: left"> </td></tr> </table>

7830

6000

6000000

1830

1830000

215

100000

15000

115

100

100000

100

100000

230000

225919

230000

4081

715000

288756

1076513

1226406

149893

328904

296032

328904

32872

69852

65062

69852

4790

496800

469116

496800

27684

SCHEDULE OF DERIVATIVE LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> Fiscal Year 2023 $ </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Fiscal Year 2022 $ </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; width: 64%">Derivative liabilities as at March 31, 2022 and 2021</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20220401__20220630_zEdS4rVcQS06" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Derivative liabilities, beginning balance">352,402</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 14%"><p id="xdx_983_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20210401__20210630_zDySHIp7szhl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right" title="Derivative liabilities, beginning balance">410,042</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Change in fair value of derivatives during the period</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_pp0p0_di_c20220401__20220630_zIqjqqFUv4Wd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in fair value of derivatives during the period">195,521</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"><p id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_pp0p0_di_c20210401__20210630_zA0KiaZcEFgg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right" title="Change in fair value of derivatives during the period">(203,525</td> <td style="font: 10pt Times New Roman, Times, Serif">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Reduction due to preferred shares redeemed</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_ecustom--ReductionDueToPreferredSharesRedeemed_c20220401__20220630_zUvLIhQGPhdb" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Reduction due to preferred shares redeemed">(10,605</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td id="xdx_983_ecustom--ReductionDueToPreferredSharesRedeemed_c20210401__20210630_z8e1fUW5m226" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Reduction due to preferred shares redeemed">-</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: bold 10pt Times New Roman, Times, Serif">Derivative liabilities as at June 30, 2022 and 2021</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20220701__20220930_zQxol0XbJMie" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities, beginning balance">537,318</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_983_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20210701__20210930_zAPUus7IrOOb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities, beginning balance">206,517</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: normal 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: normal 10pt Times New Roman, Times, Serif">New issuance</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20220701__20220930_zAp67zJHpU32" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in fair value new issuance">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20210701__20210930_ziX35yubUQtd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in fair value new issuance">17,084</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Change in fair value of derivatives during the period</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_pp0p0_di_c20220701__20220930_z1HUiDOOJS26" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in fair value of derivatives during the period">168,762</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_pp0p0_di_c20210701__20210930_zGgTlJlMeMHd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in fair value of derivatives during the period">(101,173</td> <td style="font: 10pt Times New Roman, Times, Serif">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Reduction due to preferred shares redeemed</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_ecustom--ReductionDueToPreferredSharesRedeemed_c20220701__20220930_z1GVFk1GJzR5" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Reduction due to preferred shares redeemed">(4,444</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td id="xdx_98B_ecustom--ReductionDueToPreferredSharesRedeemed_c20210701__20210930_zBWENkaXMUyf" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Reduction due to preferred shares redeemed">-</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: bold 10pt Times New Roman, Times, Serif">Derivative liabilities as at September 30, 2022 and 2021</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20221001__20221231_z0wkPVFzyRNb" style="font: normal 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities, beginning balance">701,636</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_981_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20211001__20211231_zdxbrmoUBwrf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities, beginning balance">121,828</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Change in fair value of derivatives during the period</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_pp0p0_di_c20221001__20221231_zlvrHgvi4u8j" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in fair value of derivatives during the period">78,026</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_pp0p0_di_c20211001__20211231_zno84zM2ze3l" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in fair value of derivatives during the period">644,774</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Reduction due to preferred shares redeemed</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_ecustom--ReductionDueToPreferredSharesRedeemed_c20221001__20221231_zoQ5XUmwAgn6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Reduction due to preferred shares redeemed">(37,987</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td id="xdx_988_ecustom--ReductionDueToPreferredSharesRedeemed_c20211001__20211231_zwQ60Umqoal1" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Reduction due to preferred shares redeemed">(479,791</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif">Derivative liabilities as at December 31, 2022 and 2021</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--DerivativeLiabilities_iE_pp0p0_c20221001__20221231_zAOMKtJ8Zi53" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities, ending balance">741,675</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_988_eus-gaap--DerivativeLiabilities_iE_pp0p0_c20211001__20211231_zyIHvo84veg5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities, ending balance">286,811</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> </table>

352402

410042

-195521

203525

-10605

537318

206517

17084

-168762

101173

-4444

701636

121828

-78026

-644774

-37987 -479791

741675

286811

The lattice methodology was used to value the derivative components, using the following assumptions: SCHEDULE OF DERIVATIVE COMPONENTS VALUATION ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Dividend yield (%)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: right"><span id="xdx_901_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z8xcOpkq5ojc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</td><td style="width: 1%; text-align: left"/></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free rate for term (%)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z0qXDFpOl4b6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.18 – <span id="xdx_90F_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zqtEQMgxPrl5">4.36</td><td style="text-align: left"/></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility (%)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zEYbZB9wXZT1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">92.7 – <span id="xdx_903_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zs5sT301Esvc">93.6</td><td style="text-align: left"/></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Remaining terms (Years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20220401__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zgKAzZ31n5ug" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.00 to <span id="xdx_90A_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20220401__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zTdd6gIsaDy4">2.50</td><td style="text-align: left"/></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Stock price ($ per share)</td><td> </td> <td style="text-align: left"/><td style="text-align: right">0.45 to 0.72</td><td style="text-align: left"> </td></tr> </table>

4.18

4.36

92.7

93.6

P1Y P2Y6M 0.45 0.72

<p id="xdx_891_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_hus-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z2HMfY0Ms4h6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">SCHEDULE OF DERIVATIVE LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Fiscal Year 2023 $</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">Fiscal Year 2022 $ </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: italic bold 10pt Times New Roman, Times, Serif; width: 64%">Balance at March 31, 2022 and 2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pp0p0_c20220401__20220630__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z3qjILj325ol" style="font: bold 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Derivative liabilities, beginning balance">520,747</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 14%"><p id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pp0p0_c20210401__20210630__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zez1EfdSgTJ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right" title="Derivative liabilities, beginning balance">3,633,856</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Conversion to common shares</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--ConversionOfStockAmountConverted1_pp0p0_c20220401__20220630__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zngWkCZgTkUl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Conversion to common shares">(104,118</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"><p id="xdx_987_eus-gaap--ConversionOfStockAmountConverted1_pp0p0_c20210401__20210630__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zf2XOfGLmRga" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right" title="Conversion to common shares">(403,108</td> <td style="font: 10pt Times New Roman, Times, Serif">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Change in fair value of derivative liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_pp0p0_di_c20220401__20220630__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zKPezGWaCoW" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in fair value of derivatives">2,703</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_pp0p0_di_c20210401__20210630__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zGzN594g15Kf" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in fair value of derivatives">502,508</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: italic bold 10pt Times New Roman, Times, Serif">Balance at June 30, 2022 and 2021</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pp0p0_c20220701__20220930__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zN8n9YfhI0x6" style="font: normal 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities, beginning balance">419,332</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"><p id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pp0p0_c20210701__20210930__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zLJFvU5Pbasd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right" title="Derivative liabilities, beginning balance">3,733,256</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Conversion to common shares</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--ConversionOfStockAmountConverted1_pp0p0_c20220701__20220930__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zXk3cQ725Nhi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Conversion to common shares">(35,274</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"><p id="xdx_98D_eus-gaap--ConversionOfStockAmountConverted1_pp0p0_c20210701__20210930__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zI2W6rgv7V8c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right" title="Conversion to common shares">(2,744,711</td> <td style="font: 10pt Times New Roman, Times, Serif">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Change in fair value of derivative</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_pp0p0_di_c20220701__20220930__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z2jJuut8yile" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in fair value of derivative liabilities">3,280</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_pp0p0_di_c20210701__20210930__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zCUoHyQsc2s1" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in fair value of derivative liabilities">(295,801</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: italic bold 10pt Times New Roman, Times, Serif">Balance at September 30, 2022 and 2021</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pp0p0_c20221001__20221231__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z6OWeeAZtwhl" style="font: normal 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities, beginning balance">387,338</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"><p id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pp0p0_c20211001__20211231__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zbHVVYaK1EF6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right" title="Derivative liabilities, beginning balance">692,744</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Convertible note modification</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_ecustom--ConversionOfStockAmountModification_pp0p0_c20221001__20221231__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zHYF3ilP0rh8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Conversion to modification">14,083 </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Convertible note redemption</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities, beginning balance"><p id="xdx_980_ecustom--ConversionOfStockAmountRedemption_pp0p0_c20221001__20221231__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zcsLCW85CJRe" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Conversion to redemption">(17,979</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Conversion to common shares</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--ConversionOfStockAmountConverted1_pp0p0_c20221001__20221231__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zlrVeFwjlAXc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Conversion to common shares">(53,402</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_989_eus-gaap--ConversionOfStockAmountConverted1_pp0p0_c20211001__20211231__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zeGfr5VpBbhb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Conversion to common shares">(250,738</td> <td style="font: 10pt Times New Roman, Times, Serif">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Change in fair value of derivative</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_pp0p0_di_c20221001__20221231__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zWpgaRhH1yag" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in fair value of derivative liabilities">21,679</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_pp0p0_di_c20211001__20211231__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zCb2J1jr3CTl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right" title="Change in fair value of derivative liabilities">129,999</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: italic bold 10pt Times New Roman, Times, Serif">Balance at December 31, 2022 and 2021</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pp0p0_c20221001__20221231__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zezHKnPXld59" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities, beginning balance">351,719</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"><p id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pp0p0_c20211001__20211231__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zBk1Qy6HeIac" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right" title="Derivative liabilities, beginning balance">572,005</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> </table>

520747

3633856

-104118

-403108

-2703

-502508

419332

3733256

-35274

-2744711

-3280

295801

387338

692744

14083 -17979

-53402

-250738

-21679

-129999

351719

572005

<p id="xdx_893_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_hus-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zQq65I4AOd2j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The monte-carlo methodology was used to value the convertible note derivative components, using the following assumptions: SCHEDULE OF WARRANT DERIVATIVE COMPONENTS VALUATION ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">December 2022</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Risk-free rate for term (%)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: right"><span id="xdx_906_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--DebtInstrumentAxis__custom--ConversionAndRedemptionFeaturesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zhy3ypyeYhR1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.74 - <span id="xdx_900_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--ConversionAndRedemptionFeaturesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zIPHuyV3WDtk">4.37</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Volatility (%)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--DebtInstrumentAxis__custom--ConversionAndRedemptionFeaturesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_ztaIqmXw13j2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">90.4 - <span id="xdx_90D_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--ConversionAndRedemptionFeaturesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zpYMSGR44afi">99.6</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Remaining terms (Years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20220401__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--DebtInstrumentAxis__custom--ConversionAndRedemptionFeaturesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zcZTZODpx2Z2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.50 - <span id="xdx_903_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20220401__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--ConversionAndRedemptionFeaturesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z23tfOB1HWP5">0.75</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Stock price ($ per share)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_ecustom--DerivativeStockPrice_iI_pid_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--DebtInstrumentAxis__custom--ConversionAndRedemptionFeaturesMember_zsdRf88BGWB7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.50 - 1.00</td><td style="text-align: left"> </td></tr> </table>

3.74

4.37

90.4

99.6

P0Y6M P0Y9M 0.50 1.00

9. STOCKHOLDERS’ EQUITY (DEFICIENCY) a) Authorized stock As at December 31, 2022, the Company is authorized to issue 125,000,000 (March 31, 2022 – 125,000,000) shares of common stock ($0.001 par value) and 10,000,000 (March 31, 2022 – 10,000,000) shares of preferred stock ($0.001 par value), 20,000 of which are designated shares of Series A preferred stock ($0.001 par value) as of December 31, 2022 and March 31, 2022. BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022 (Unaudited) (Expressed in US dollars) At December 31, 2022, common shares and shares directly exchangeable into equivalent common shares that were issued and outstanding totaled <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220401__20221231__srt--TitleOfIndividualAxis__custom--ShareholdersMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_ztYHcIlvuk3k">52,242,072 (March 31, 2022 – <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210401__20220331__srt--TitleOfIndividualAxis__custom--ShareholdersMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_z3BmLhWUTJxf">51,277,040); these were comprised of 50,775,354 (March 31, 2022 – 49,810,322) shares of common stock and 1,466,718 (March 31, 2022 – 1,466,718) exchangeable shares. There is currently one share of the Special Voting Preferred Stock issued and outstanding, held by one holder of record, which is the Trustee in accordance with the terms of the Trust Agreement. The Company has also issued a Series A preferred stock, $0.001 par value; 20,000 shares have been designated as authorized (as at December 31, 2022 and March 31, 2022); 6,305 Series A preferred shares were issued and outstanding as at December 31, 2022 (March 31, 2022: 7,201). b) Exchange Agreement On February 2, 2016, the Company was formed through reverse-take-over: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_90A_ecustom--CommonStockExchangeDescription_c20160201__20160202__srt--TitleOfIndividualAxis__custom--ShareholdersMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_zjL3QVhx3Ejk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company issued approximately 1.197 shares of its common stock in exchange for each common share of iMedical held by the iMedical shareholders who in general terms, are not residents of Canada (for the purposes of the Income Tax Act (Canada). Accordingly, the Company issued 13,376,947 shares;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_903_ecustom--CommonStockExchangeDescription_c20160201__20160202__srt--TitleOfIndividualAxis__custom--ExchangecoMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_zrmfsHrsP4k8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholders of iMedical who in general terms, are Canadian residents (for the purposes of the Income Tax Act (Canada)) received approximately 1.197 Exchangeable Shares in the capital of Exchangeco in exchange for each common share of iMedical held. Accordingly, the Company issued <span id="xdx_908_ecustom--NumberOfExchangeableSharesIssued_c20160201__20160202__srt--TitleOfIndividualAxis__custom--ExchangecoMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_zeciQXmzrzZh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,123,031 Exchangeable Shares;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_903_ecustom--CommonStockExchangeDescription_c20160201__20160202__srt--StatementScenarioAxis__custom--OptionsMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_zOZUZN99LYbc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each outstanding option to purchase common shares in iMedical (whether vested or unvested) was exchanged, without any further action or consideration on the part of the holder of such option, for approximately 1.197 economically equivalent replacement options with an inverse adjustment to the exercise price of the replacement option to reflect the exchange ratio of approximately 1.197:1;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_90D_ecustom--CommonStockExchangeDescription_c20160201__20160202__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_zpqlL5BwlVsh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each outstanding warrant to purchase common shares in iMedical was adjusted, in accordance with the terms thereof, such that it entitles the holder to receive approximately 1.197 shares of the common stock of the Company for each warrant, with an inverse adjustment to the exercise price of the warrants to reflect the exchange ratio of approximately 1.197:1</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_901_ecustom--CommonStockExchangeDescription_c20160201__20160202__us-gaap--StatementEquityComponentsAxis__custom--AdvisorWarrantMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_zS52um8v8lOi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each outstanding advisor warrant to purchase common shares in iMedical was adjusted, in accordance with the terms thereof, such that it entitles the holder to receive approximately 1.197 shares of the common stock of the Company for each advisor warrant, with an inverse adjustment to the exercise price of the Advisor Warrants to reflect the exchange ratio of approximately 1.197:1; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_90D_eus-gaap--ConversionOfStockDescription_c20160201__20160202__us-gaap--DebtInstrumentAxis__custom--ElevenPercentageSecuredConvertiblePromissoryNotesMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_zvvakrTOLwX2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The outstanding 11% secured convertible promissory notes of iMedical were adjusted, in accordance with the adjustment provisions thereof, as and from closing, so as to permit the holders to convert (and in some circumstances permit the Company to force the conversion of) the convertible promissory notes into shares of the common stock of the Company at a <span id="xdx_909_ecustom--DiscountPercentageForPurchasePricePerShares_pid_dp_uPure_c20160201__20160202__us-gaap--DebtInstrumentAxis__custom--ElevenPercentageSecuredConvertiblePromissoryNotesMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_zpLwUSFGN2z2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25% discount to purchase price per share in Biotricity’s next offering.</td></tr> </table> Issuance of common stock, exchangeable shares and cancellation of shares in connection with the reverse takeover transaction as explained above represents recapitalization of capital retroactively adjusting the accounting acquirer’s legal capital to reflect the legal capital of the accounting acquiree. c) Series (A) Preferred Stock The number of Series A Preferred Stock issued and outstanding as of December 31, 2022 and March 31, 2022 was 6,305 and 7,201, respectively. The Series A Preferred Stock is junior to the Company’s existing undesignated preferred stock, and unless otherwise set forth in the applicable certificate of designations, shall be junior to any future issuance of preferred stock. The purchase price (the “Purchase Price”) for the Series A Preferred Stock to date has been $1,000 per share. Except as otherwise expressly required by law, the Series A Preferred Stock does not have voting rights and does not have any liquidation rights. Preferred Stock Dividends Dividends shall be paid at the rate of 12% per annum of the amount of the Series A Preferred Stockholder’s (the “Holder”) Purchase Price. Dividends shall be paid quarterly unless the Holder and the Company mutually agree to accrue and defer any such dividend. Conversion The Series A Preferred Stock is convertible into shares of common stock commencing 24 months after the issuance date of the Series A Preferred Stock. Upon which, on a monthly basis, up to 5% of the aggregate amount of the Purchase Price can be converted (subject to adjustment for changes in the Holder’s ownership of the underlying Series A Preferred Stock). The conversion price is equal to the greater of $.001 or a 15% discount to the volume-weighted average price (“VWAP”) of the Company’s common stock five Trading Days immediately prior to the conversion date (the “Conversion Rate). Additionally, subject to certain provisions, the Holder may exchange its Series A Preferred Stock into any common stock financing being conducted by the Company at a 15% discount to the pricing of that financing. Other Adjustments and Rights ● The Conversion Rate (and shares issuable upon conversion of the Series A Preferred Stock) will be appropriately adjusted to reflect stock splits, stock dividends business combinations and similar recapitalization. ● The Holders shall be entitled to a proportionate share of certain qualifying distributions on the same basis as if they were holders of the Company’s common stock on an as converted basis. BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022 (Unaudited) (Expressed in US dollars) Company Redemption The Company may redeem all or part of the outstanding Series A Preferred Stock after one year from the date of issuance by paying an amount equal to the aggregate Purchase Price paid, adjusted for any reduction in Series A Preferred Stock holdings, multiplied by 110% plus accrued dividends d) Share issuances Share issuances during the year ended March 31, 2022 During the year ended March 31, 2022, the Company issued 4,696,083 common shares (not including 19,263 shares that were part of to be issued shares from prior year conversions) in connection with conversion of convertible notes. The total amounts of debts settled is in amount of $14,522,812 that composed of face value of convertible promissory notes in amount of $10,309,000, carrying amount of conversion and redemption feature derived from notes in amount of $3,398,557 and unpaid interest in amount of $815,255. The fair value of the shares issued was determined based on the market price upon conversion and was in the amount of $15,678,454. The difference between amounts of debts settled and fair value of common shares issued was in the amount of $1,155,642 and was recorded as loss on conversion of convertible promissory notes in statement of operations. During the year ended March 31, 2022, the Company issued 658,355 common shares in connection with warrant exercises for cash, and 446,370 common shares in connection with cashless warrant exercises (Note 9f). In addition, the Company issued 451,688 common shares for services provided (not including 250,000 that were part of to be issued shares from prior year commitment). The fair value of common shares issued for services provided was $1,414,449. The fair value of common shares was determined based on the fair value on the date of approval of common share issuance. During the year ended March 31, 2022, the Company issued 69,252 common shares for cash proceeds of $250,000, which were initially received as a promissory note, and paid through the issuance common shares within the same quarter. During the year ended March 31, 2022, the Company issued 5,382,331 common shares in connection with the equity financing that was concurrent with its listing on the Nasdaq Capital Market, for total net cash proceeds of $14,545,805. During the year ended March 31, 2022, an additional 100 Series A preferred shares were issued for cash proceeds of $100,000. The Company issued 288,756 common shares as a result of preferred share conversions (Note 8). During the year ended March 31, 2022, the Company also issued an aggregate of 1,423,260 shares of its common stock to investors as part of the one-for-one exchange of previously issued exchangeable shares into the Company’s Common Stock, which is a non-cash transaction. Share issuances during the three months ended June 30, 2022 During the three months ended June 30, 2022, the Company issued 404,545 common shares in connection with conversion of convertible notes (Note 5). The total amounts of debts settled is in amount of $406,118 that composed of face value of convertible promissory notes in amount of $302,000 (Note 5), carrying amount of conversion and redemption feature derived from notes in amount of $104,118. The fair value of the shares issued and to be issued was determined based on the market price upon conversion and was in the amount of $457,025. The difference, that represented a loss on conversion between amounts of debt settled and fair value of common shares issued, was in the amount of $50,908 and was recorded as loss on conversion of convertible promissory notes in statement of operations. During the three months ended June 30, 2022, the Company removed 40,094 of previously to be issued shares, in connection with cancellation of warrant exercises from certain warrant holders. In addition, the Company recognized additional 11,792 shares to be issued for warrant exercise request received but not processed as of quarter end. As a result of the cancellation of to be issued shares, $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationForfeited_c20220401__20220630__srt--StatementScenarioAxis__custom--IssuanceOfCommonSharesMember__srt--RangeAxis__srt--MinimumMember_zlDscQwCr7ka">42,500 was reduced from balance of shares to be issued, and the Company increased the balance of the shares to be issued by $12,500 upon the warrants exercise. During the three months ended June 30, 2022, the Company issued 4,167 common shares for services received, with a fair value of $7,500. Share issuances during the three months ended September 30, 2022 During the three months ended September 30, 2022, the Company issued 117,647 common shares in connection with conversion of convertible notes (Note 5). The total amounts of debts settled is in amount of $135,274 that composed of face value of convertible promissory notes in amount of $100,000 (Note 5), carrying amount of conversion and redemption feature derived from notes in amount of $35,274. The fair value of the shares issued and to be issued was determined based on the market price upon conversion and was in the amount of $175,294. The difference, that represented a loss on conversion, between amounts of debts settled and fair value of common shares issued was in the amount of $40,020 and was recorded as loss on conversion of convertible promissory notes in statement of operations. During the three months ended September 30, 2022, the Company issued 22,772 common shares for services received, with a fair value of $30,287. BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022 (Unaudited) (Expressed in US dollars) Share issuances during the three months ended December 31, 2022 During the three months ended December 31, 2022, the Company issued 238,846 common shares in connection with the conversion of convertible notes (Note 5). The total amounts of debts settled is in amount of $207,002 that composed of face value of convertible promissory notes in amount of $153,600 (Note 5), carrying amount of conversion and redemption feature derived from notes in amount of $53,402. The fair value of the shares issued and to be issued was determined based on the market price upon conversion and was in the amount of $211,602. The difference, that represented a loss on conversion, between amounts of debts settled and fair value of common shares issued was in the amount of $4,600 and was recorded as loss on conversion of convertible promissory notes in condensed consolidated statements of operations and comprehensive loss. In addition, the Company issued 105,263 common shares for services received with a fair value of $112,631 which was recognized as a general and administrative expense with a corresponding credit to additional paid-in capital. e) Shares to be issued During the nine months ended December 31, 2022, the Company issued 100,094 shares in satisfaction of its obligation of shares to be issued, and moved $77,300 out of the shares to be issued account into the additional paid in capital account. f) Warrant issuances, exercises and other activity Warrant exercises and issuances during the year ended March 31, 2022 During the year ended March 31, 2022, 658,355 warrants were exercised pursuant to receipt of exercise proceeds of $872,292. 446,370 warrants were exercised pursuant to cashless warrant exercise. In addition, $103,950 warrant exercise proceeds receivable was recorded as part of deposit and other receivables as of March 31, 2022. During the year ended March 31, 2022, the Company issued <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationGross_c20210401__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--AdvisorAndConsultantMember_zTy3jScsQVpb">212,594 warrants, including 25,000 as compensation for advisor and consultant services, and <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationGross_c20210401__20220331__srt--TitleOfIndividualAxis__srt--ExecutiveOfficerMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuKpuFOOdkj9">187,594 as compensation to an executive of the Company who was not part of the Company stock options plan. The warrant expenses were fair valued at $541,443, and recognized as general and administrative expenses, with a corresponding credit to additional paid-in capital. During the year ended March 31, 2022, the Company issued <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220331__srt--TitleOfIndividualAxis__custom--LendersMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zizPCgk8RTb7">57,536 share purchase warrants to lenders in connection with the term loan (Note 6). The fair value of these warrants, in the amount of $198,713, was recorded as part of the discount of the loan, with a corresponding credit to additional paid-in capital. The warrants were not considered as derivative instruments. The fair value of these warrants was determined by using the Black Scholes model, based on the following key inputs and assumptions: expiry date <span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpirationDate_dd_c20210401__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--LendersMember_zw7xAabdvzJd">December 21, 2028, exercise price $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--LendersMember_zxAlk40LgTd4">6.26, rate of return <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210401__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--LendersMember_z7Hc0DsUojxe">1.40%, and volatility <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210401__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--LendersMember_zuxkubQzvvE8">121.71%. During the year ended March 31, 2022, the Company issued <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220331__srt--TitleOfIndividualAxis__custom--UnderwriterMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBcZWEeNFvrf">373,404 share purchase warrants to underwriter. The warrants were not considered as a derivative instrument and were accounted as additional paid-in capital along with the uplisting transaction. The warrants were fair valued at $900,371. The fair value of these warrants was determined by using Black Scholes model, based on the following key inputs and assumptions: expiry date <span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpirationDate_dd_c20210401__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--UnderwriterMember_zPqQGayl6OPl">August 26, 2026, exercise price $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--UnderwriterMember_zLjWnZ2iyhRf">3.75, rate of returns <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210401__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--UnderwriterMember_zZeYTIp6pyma">0.77%, and volatility <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210401__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--UnderwriterMember_zTuwwOCP8WMl">111.9%. Warrant exercises and issuances during the three months ended June 30, 2022 During the three months ended June 30, 2022, the Company issued <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220401__20220630__srt--TitleOfIndividualAxis__custom--ExecutiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfUNz1DN30n8">53,827 warrants as compensation to an executive of the Company who was not part of the Company stock options plan. The warrant expenses were fair valued at $77,414, and recognized as general and administrative expenses, with a corresponding credit to additional paid-in capital. Warrant exercises and issuances during the three months ended September 30, 2022 During the three months ended September 30, 2022, the Company issued <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220701__20220930__srt--TitleOfIndividualAxis__custom--ExecutiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z05MN3GBcV79">118,282 warrants as compensation to an executive of the Company who was not part of the Company stock options plan. The warrant expenses were fair valued at $77,332, and recognized as general and administrative expenses, with a corresponding credit to additional paid-in capital. BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022 (Unaudited) (Expressed in US dollars) Warrant issuances and exchanges into other securities during the three months ended December 31, 2022 During the three months ended December 31, 2022, the Company issued <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--ExecutiveMember_zmEWwgsJMJ3c">218,785 warrants as compensation to an executive of the Company who was not part of the Company stock options plan. The fair value of the warrants at issuance was $77,780 and was recognized as a general and administrative expense, with a corresponding credit to additional paid-in capital. In addition, the Company added 312,500 warrants to its outstanding warrant schedule in connection with warrants issued to Series B convertible note holders. This has no impact on paid-in capital as the fair value of warrants were already accounted for as part of the original Series B convertible note issuance accounting entries. Lastly, the Company extinguished and exchanged 306,604 warrants for promissory notes [Note 5] that resulted in an adjustment to additional paid-in capital in the amount of $71,768. Warrant issuances, exercises and expirations or cancellations during the three months ended December 31, 2022 and preceding periods resulted in warrants outstanding at the end of those respective periods as follows: SCHEDULE OF WARRANTS OUTSTANDING <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4BA_us-gaap--StatementEquityComponentsAxis_custom--BrokerAndOtherWarrantsMember_zn54fJwiAMag" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Broker and Other Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_custom--ConsultantWarrantsMember_z9Nt0Y32HlGl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Consultant Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4B6_us-gaap--StatementEquityComponentsAxis_custom--WarrantsIssuedOnConversionOfConvertibleNotesMember_zfCSiR5yYZE8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants Issued on Conversion of Convertible Notes</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4BD_zgpti01PgFn9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_43E_c20220401__20220630_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_zYKGEbwzprph" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; width: 44%">As at March 31, 2022</td><td style="font-weight: bold; width: 2%"> </td> <td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; text-align: right; width: 10%">876,205</td><td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; width: 2%"> </td> <td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; text-align: right; width: 10%">1,802,316</td><td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; width: 2%"> </td> <td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; text-align: right; width: 10%">7,211,623</td><td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; width: 2%"> </td> <td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; text-align: right; width: 10%">9,890,144</td><td style="font-weight: bold; text-align: left; width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_zFNIKpKFmXb9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Less: Expired/cancelled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,563,980</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,563,980</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_z9uwWGI7kjT7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less: Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(11,792</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(11,792</td><td style="text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_zrIEMc7HPMVb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Add: Issued</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">53,827</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">53,827</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_43E_c20220701__20220930_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_zfUxIJ9EY0m4" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 1.5pt">As at June 30, 2022</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">876,205</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,856,143</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">5,635,851</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">8,368,199</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_zjWdJvu3CEA9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less: Expired/cancelled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(37,134</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(114,583</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(151,717</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_zQNMIYPl9pIf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Less: Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_zSg0g4C3jYN6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Add: Issued</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">118,282</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">118,282</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_43F_c20221001__20221231_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_zlZzJGMWGFi8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 1.5pt">As at September 30, 2022</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">839,071</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,859,842</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">5,635,851</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">8,334,764</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_43C_c20221001__20221231_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_zmEZ5altwMea" style="display: none; vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 1.5pt">Warrant outstanding, beginning balance</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"/><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">839,071</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,859,842</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">5,635,851</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">8,334,764</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_z7NOGEV5Xms4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less: Expired/cancelled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(278,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(278,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_zA5IxMx9Rkva" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Less: Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(306,604</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(306,604</td><td style="text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_zKZcNXHni2pa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Add: Issued</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">218,785</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">531,285</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_43A_c20221001__20221231_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_zJao0Q6rx3Db" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 1.5pt">As at December 31, 2022</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">839,071</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,800,627</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">5,329,247</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">7,968,945</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_43D_c20221001__20221231_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_zXKVlfd6HRVk" style="display: none; vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 1.5pt">Warrant outstanding, ending balance</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">839,071</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,800,627</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">5,329,247</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">7,968,945</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercise Price</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">$<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--BrokerWarrantsMember__srt--RangeAxis__srt--MinimumMember_zDBfQeIe2vU9">1.06 to $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--BrokerWarrantsMember__srt--RangeAxis__srt--MaximumMember_z1vBALAGlHN3">6.26</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">$<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--ConsultantWarrantsMember__srt--RangeAxis__srt--MinimumMember_z9JT7Zx0I845">0.45 to $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--ConsultantWarrantsMember__srt--RangeAxis__srt--MaximumMember_zoypXlLkaZFk">3.15</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">$<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedOnConversionOfConvertibleNoteMember__srt--RangeAxis__srt--MinimumMember_zJqX1IYGSQUl">1.06 to $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedOnConversionOfConvertibleNoteMember__srt--RangeAxis__srt--MaximumMember_z3PHH1vs3rEk">1.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expiration Date</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20220401__20221231__us-gaap--StatementEquityComponentsAxis__custom--BrokerWarrantsMember_z457UZLdrkPj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2026 to January 2031</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20220401__20221231__us-gaap--StatementEquityComponentsAxis__custom--ConsultantWarrantsMember_zBTCPu8ShHgc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 2023 to December 2032</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20220401__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedOnConversionOfConvertibleNotesMember_zpE41xxYEJ7e" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 2024 to February 2024</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> </table> BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022 (Unaudited) (Expressed in US dollars) g) Stock-based compensation On February 2, 2016, the Board of Directors of the Company approved the Company’s 2016 Equity Incentive Plan (the “Plan”). The purpose of the Plan is to advance the interests of the Company and its stockholders by providing an incentive to attract, retain and reward persons performing services for the Company and by motivating such persons to contribute to the growth and profitability of the Company. The Plan seeks to achieve this purpose by providing for awards in the form of options, stock appreciation rights, restricted stock purchase rights, restricted stock bonuses, restricted stock units, performance shares, performance units and other stock-based awards. The Plan shall continue in effect until its termination by the board of directors or committee formed by the board; provided, however, that all awards shall be granted, if at all, on or before the day immediately preceding the tenth (10th) anniversary of the effective date. The maximum number of shares of stock that may be issued under the Plan shall be equal to <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20160202__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember_zFsApj2J3b6g">3,750,000 shares; provided that the maximum number of shares of stock that may be issued under the Plan pursuant to awards shall automatically and without any further Company or shareholder approval, increase on January 1 of each year for not more than 10 years from the effective date, so the number of shares that may be issued is an amount no greater than 20% of the Company’s outstanding shares of stock and shares of stock underlying any outstanding exchangeable shares as of such January 1; provided further that no such increase shall be effective if it would violate any applicable law or stock exchange rule or regulation, or result in adverse tax consequences to the Company or any participant that would not otherwise result but for the increase. Based on the 2016 Option Plan, the Company is authorized to issue employee options with a <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220401__20221231__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember__srt--TitleOfIndividualAxis__custom--EmployeeMember_zUHG0yc6lD6l">10-year term. On March 31, 2020, the Company’s Board of Directors approved the amendment of certain prior options grants, issued to current employees, previously issued with a <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190401__20200331__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember__srt--TitleOfIndividualAxis__custom--EmployeeMember_z1ex1i1QiwJe">3-year term, such that the respective options issued under these agreements would have their term extended to <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190401__20200331__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember_zFwi6OU9uEI6">10 years. The Company revalued these options using a lattice model with an expected life of <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190401__20200331__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorMember_zPJfKNRJGX9j">10 years, risk free rates of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20190401__20200331__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember__srt--RangeAxis__srt--MinimumMember_zYO4gj9g7oMa">0.46% to <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20190401__20200331__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zcmyFUL7igic">0.75%, stock price of $0.974 and expected volatility of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20190401__20200331__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember_zyiZY7ePY3u">132.2%, in order to recognize the additional expense associated with the longer term and recognized a one-time charge of $1,600,515 in share-based compensation, with a corresponding adjustment to adjusted paid in capital. During the three months ended June 30, 2022, the Company granted <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20220401__20220630__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember_zPV4qmTygLej">10,180 of options with a weighted average remaining contractual life of <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220401__20220630__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember_zKppMOEaelb8">10 years. The Company recorded stock-based compensation of $149,190 in connection with ESOP 2016 Plan (June 30, 2021 - $155,851), under general and administrative expenses with corresponding credit to additional paid in capital. During the three months ended September 30, 2022, the Company granted <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20220701__20220930__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember_zoRAqjCtgio2">3,757 of options with a weighted average remaining contractual life of <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220701__20220930__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember_zVFsjDeyb4c3">10 years. The Company recorded stock-based compensation of $153,338 in connection with ESOP 2016 Plan (September 30, 2021 - $169,778), under general and administrative expenses with corresponding credit to additional paid in capital. During the three months ended December 31, 2022, the Company granted no new options. The Company recorded stock-based compensation of $63,125 in connection with ESOP 2016 Plan (December 31, 2021 - $100,650), under general and administrative expenses with corresponding credit to additional paid in capital. BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022 (Unaudited) (Expressed in US dollars) The following table summarizes the stock option activities of the Company to December 31, 2022: SCHEDULE OF STOCK OPTION ACTIVITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of options</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average exercise price ($)</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; width: 60%">Outstanding as of March 31, 2022</td><td style="font-weight: bold; width: 2%"> </td> <td style="font-weight: bold; text-align: left; width: 1%"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220401__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zqezH9mrgwB5" style="font-weight: bold; text-align: right; width: 16%" title="Number of options, beginning outstanding">7,409,714</td><td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; width: 2%"> </td> <td style="font-weight: bold; text-align: left; width: 1%"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220401__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zLrrrLdjpuxd" style="font-weight: bold; text-align: right; width: 16%" title="Weighted average exercise price, beginning outstanding">2.3466</td><td style="font-weight: bold; text-align: left; width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220401__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zlJOWlOiJxHj" style="text-align: right" title="Number of options, granted">10,180</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220401__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zxrt9JYuagc8" style="text-align: right" title="Weighted average exercise price, granted">1.7700</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20220401__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zqztiju3ciLh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options, exercised">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220401__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zpL9sCdTVKof" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, exercised">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Outstanding as of June 30, 2022</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220701__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zWHF0FpP2qb8" style="font-weight: bold; text-align: right" title="Number of options, beginning outstanding">7,419,894</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220701__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zlIBYiPhu7Ke" style="font-weight: bold; text-align: right" title="Weighted average exercise price, beginning outstanding">2.3458</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Granted</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220701__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zsKz63AkZoF3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options, granted">3,757</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220701__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zU9dUVOVEC7c" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, granted">2.2700</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Outstanding as of September 30, 2022</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20221001__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zSmkJRXq8MC6" style="font-weight: bold; text-align: right" title="Number of options, beginning outstanding">7,423,651</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20221001__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zZac14kagUF4" style="font-weight: bold; text-align: right" title="Weighted average exercise price, beginning outstanding">2.3457</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20221001__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zwG8YZuT11Qi" style="text-align: right" title="Number of options, granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20221001__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zMQsYR1nYlU2" style="text-align: right" title="Weighted average exercise price, granted">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20221001__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zq9D0gVS8Jb7" style="text-align: right" title="Number of options, expired">(16,733</td><td style="text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20221001__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zfZIssRmbpjh" style="text-align: right" title="Weighted average exercise price, expired">1.3671</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20221001__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zcGjmaGHf9p2" style="text-align: right" title="Number of options, forfeited">(88,084</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20221001__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zsb5x36G2zgh" style="text-align: right" title="Weighted average exercise price, forfeited">1,9710</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20221001__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zYj54WTrcpCe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options, exercised">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20221001__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zLIqR1KIGznb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, exercised">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 1.5pt">Outstanding as of December 31, 2022</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20221001__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zKhSiscIzFu" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Number of options, ending outstanding">7,318,834</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20221001__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zulqZXVzPOX" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Weighted average exercise price, ending outstanding">2.3509</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> </table> BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022 (Unaudited) (Expressed in US dollars) <p id="xdx_899_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zP1KYP66RH8c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The fair value of each option granted is estimated at the time of grant using the Black Scholes model using the following assumptions, for each of the respective fiscal year: SCHEDULE OF FAIR VALUE OF OPTION GRANTED USING VALUATION ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Fiscal Year 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Fiscal Year 2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> </tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">Exercise price ($)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20230331__srt--StatementScenarioAxis__srt--ScenarioForecastMember__srt--RangeAxis__srt--MinimumMember_zr9ItDiHqdg5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.77 – <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20230331__srt--StatementScenarioAxis__srt--ScenarioForecastMember__srt--RangeAxis__srt--MaximumMember_z9DsUjf5HOOh">2.27</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220331__srt--RangeAxis__srt--MinimumMember_z85DLAJoZZ5f" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.40 – 3.98</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td> </tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk free interest rate (%)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220401__20230331__srt--StatementScenarioAxis__srt--ScenarioForecastMember__srt--RangeAxis__srt--MinimumMember_zYmnT6Mw8XSi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.00 – <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220401__20230331__srt--StatementScenarioAxis__srt--ScenarioForecastMember__srt--RangeAxis__srt--MaximumMember_zkReIlZOynul">4.06</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20210401__20220331__srt--RangeAxis__srt--MinimumMember_z6OnFXgvMRih" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.34 – <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20210401__20220331__srt--RangeAxis__srt--MaximumMember_zhHyh2LXFlAi">2.32</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> </tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected term (Years)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220401__20230331__srt--StatementScenarioAxis__srt--ScenarioForecastMember__srt--RangeAxis__srt--MinimumMember_zIxxvY2P2sM2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 – <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220401__20230331__srt--StatementScenarioAxis__srt--ScenarioForecastMember__srt--RangeAxis__srt--MaximumMember_zyRVdyAyB1F2">6.5</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210401__20220331__srt--RangeAxis__srt--MinimumMember_zlBWcmUPmX53" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.0 – 10.0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> </tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected volatility (%)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20220401__20230331__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zO8CCsMqRtA9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">107.7 – 119.5</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20210401__20220331__srt--RangeAxis__srt--MinimumMember_z5GUUzO0J8L7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">106.6 – <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20210401__20220331__srt--RangeAxis__srt--MaximumMember_z5Is9GtK2yQ6">129.9</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> </tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected dividend yield (%)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220401__20230331__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zPfaozdmc884" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Expected dividend yield">0.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210401__20220331_z7TZrlbpNKNi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Expected dividend yield">0.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> </tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Fair value of option ($)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20230331__srt--StatementScenarioAxis__srt--ScenarioForecastMember__srt--RangeAxis__srt--MinimumMember_zyzjtL0sngNk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.36 – <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20230331__srt--StatementScenarioAxis__srt--ScenarioForecastMember__srt--RangeAxis__srt--MaximumMember_z1cL0HPu3K8d">1.57</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20220331__srt--RangeAxis__srt--MinimumMember_znTOerpoJEYb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.19 – 3.52</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> </tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected forfeiture (attrition) rate (%)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_ecustom--ExpectedForfeitureAttritionRates_pid_dp_uPure_c20220401__20230331__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zmuGMPClhvG5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Expected forfeiture (attrition) rate">0.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_ecustom--ExpectedForfeitureAttritionRates_pid_dp_uPure_c20210401__20220331_zvg7M8lBowze" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Expected forfeiture (attrition) rate">0.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> </tr> </table>

125000000

0.001

10000000

0.001

20000

0.001

52242072

51277040

50775354

49810322

1466718

0.001

20000

6305

7201

The Company issued approximately 1.197 shares of its common stock in exchange for each common share of iMedical held by the iMedical shareholders who in general terms, are not residents of Canada (for the purposes of the Income Tax Act (Canada)

13376947

Shareholders of iMedical who in general terms, are Canadian residents (for the purposes of the Income Tax Act (Canada)) received approximately 1.197 Exchangeable Shares in the capital of Exchangeco in exchange for each common share of iMedical held. Accordingly, the Company issued 9123031 Each outstanding option to purchase common shares in iMedical (whether vested or unvested) was exchanged, without any further action or consideration on the part of the holder of such option, for approximately 1.197 economically equivalent replacement options with an inverse adjustment to the exercise price of the replacement option to reflect the exchange ratio of approximately 1.197:1 Each outstanding warrant to purchase common shares in iMedical was adjusted, in accordance with the terms thereof, such that it entitles the holder to receive approximately 1.197 shares of the common stock of the Company for each warrant, with an inverse adjustment to the exercise price of the warrants to reflect the exchange ratio of approximately 1.197:1 Each outstanding advisor warrant to purchase common shares in iMedical was adjusted, in accordance with the terms thereof, such that it entitles the holder to receive approximately 1.197 shares of the common stock of the Company for each advisor warrant, with an inverse adjustment to the exercise price of the Advisor Warrants to reflect the exchange ratio of approximately 1.197:1; and

The outstanding 11% secured convertible promissory notes of iMedical were adjusted, in accordance with the adjustment provisions thereof, as and from closing, so as to permit the holders to convert (and in some circumstances permit the Company to force the conversion of) the convertible promissory notes into shares of the common stock of the Company at a

0.25

6305

7201

1000

0.12

0.05

0.001

0.15

1.10

4696083

19263

14522812

10309000

3398557

815255

15678454

1155642

658355

446370

451688

250000

1414449

69252

250000

5382331

14545805

100

100000

288756

1423260

404545 406118

302000

104118

457025

50908 40094 11792

42500

12500

4167

7500

117647 135274

100000

35274

175294

40020

22772

30287

238846

207002

153600

53402

211602

4600

105263

112631

100094 77300

658355

872292 446370

103950

212594

25000

187594

541443

57536

198713

2028-12-21

6.26

0.0140

1.2171

373404

900371

2026-08-26

3.75

0.0077

1.119

53827

77414

118282

77332

218785

77780

312500

306604

71768

Warrant issuances, exercises and expirations or cancellations during the three months ended December 31, 2022 and preceding periods resulted in warrants outstanding at the end of those respective periods as follows: SCHEDULE OF WARRANTS OUTSTANDING <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4BA_us-gaap--StatementEquityComponentsAxis_custom--BrokerAndOtherWarrantsMember_zn54fJwiAMag" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Broker and Other Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_custom--ConsultantWarrantsMember_z9Nt0Y32HlGl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Consultant Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4B6_us-gaap--StatementEquityComponentsAxis_custom--WarrantsIssuedOnConversionOfConvertibleNotesMember_zfCSiR5yYZE8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants Issued on Conversion of Convertible Notes</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4BD_zgpti01PgFn9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_43E_c20220401__20220630_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_zYKGEbwzprph" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; width: 44%">As at March 31, 2022</td><td style="font-weight: bold; width: 2%"> </td> <td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; text-align: right; width: 10%">876,205</td><td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; width: 2%"> </td> <td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; text-align: right; width: 10%">1,802,316</td><td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; width: 2%"> </td> <td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; text-align: right; width: 10%">7,211,623</td><td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; width: 2%"> </td> <td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; text-align: right; width: 10%">9,890,144</td><td style="font-weight: bold; text-align: left; width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_zFNIKpKFmXb9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Less: Expired/cancelled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,563,980</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,563,980</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_z9uwWGI7kjT7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less: Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(11,792</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(11,792</td><td style="text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_zrIEMc7HPMVb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Add: Issued</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">53,827</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">53,827</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_43E_c20220701__20220930_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_zfUxIJ9EY0m4" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 1.5pt">As at June 30, 2022</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">876,205</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,856,143</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">5,635,851</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">8,368,199</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_zjWdJvu3CEA9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less: Expired/cancelled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(37,134</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(114,583</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(151,717</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_zQNMIYPl9pIf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Less: Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_zSg0g4C3jYN6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Add: Issued</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">118,282</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">118,282</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_43F_c20221001__20221231_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_zlZzJGMWGFi8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 1.5pt">As at September 30, 2022</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">839,071</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,859,842</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">5,635,851</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">8,334,764</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_43C_c20221001__20221231_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_zmEZ5altwMea" style="display: none; vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 1.5pt">Warrant outstanding, beginning balance</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"/><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">839,071</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,859,842</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">5,635,851</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">8,334,764</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_z7NOGEV5Xms4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less: Expired/cancelled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(278,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(278,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_zA5IxMx9Rkva" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Less: Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(306,604</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(306,604</td><td style="text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_zKZcNXHni2pa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Add: Issued</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">218,785</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">531,285</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_43A_c20221001__20221231_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_zJao0Q6rx3Db" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 1.5pt">As at December 31, 2022</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">839,071</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,800,627</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">5,329,247</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">7,968,945</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_43D_c20221001__20221231_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_zXKVlfd6HRVk" style="display: none; vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 1.5pt">Warrant outstanding, ending balance</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">839,071</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,800,627</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">5,329,247</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">7,968,945</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercise Price</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">$<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--BrokerWarrantsMember__srt--RangeAxis__srt--MinimumMember_zDBfQeIe2vU9">1.06 to $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--BrokerWarrantsMember__srt--RangeAxis__srt--MaximumMember_z1vBALAGlHN3">6.26</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">$<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--ConsultantWarrantsMember__srt--RangeAxis__srt--MinimumMember_z9JT7Zx0I845">0.45 to $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--ConsultantWarrantsMember__srt--RangeAxis__srt--MaximumMember_zoypXlLkaZFk">3.15</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">$<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedOnConversionOfConvertibleNoteMember__srt--RangeAxis__srt--MinimumMember_zJqX1IYGSQUl">1.06 to $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedOnConversionOfConvertibleNoteMember__srt--RangeAxis__srt--MaximumMember_z3PHH1vs3rEk">1.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expiration Date</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20220401__20221231__us-gaap--StatementEquityComponentsAxis__custom--BrokerWarrantsMember_z457UZLdrkPj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2026 to January 2031</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20220401__20221231__us-gaap--StatementEquityComponentsAxis__custom--ConsultantWarrantsMember_zBTCPu8ShHgc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 2023 to December 2032</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20220401__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedOnConversionOfConvertibleNotesMember_zpE41xxYEJ7e" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 2024 to February 2024</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> </table> BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022 (Unaudited) (Expressed in US dollars) g) Stock-based compensation On February 2, 2016, the Board of Directors of the Company approved the Company’s 2016 Equity Incentive Plan (the “Plan”). The purpose of the Plan is to advance the interests of the Company and its stockholders by providing an incentive to attract, retain and reward persons performing services for the Company and by motivating such persons to contribute to the growth and profitability of the Company. The Plan seeks to achieve this purpose by providing for awards in the form of options, stock appreciation rights, restricted stock purchase rights, restricted stock bonuses, restricted stock units, performance shares, performance units and other stock-based awards. The Plan shall continue in effect until its termination by the board of directors or committee formed by the board; provided, however, that all awards shall be granted, if at all, on or before the day immediately preceding the tenth (10th) anniversary of the effective date. The maximum number of shares of stock that may be issued under the Plan shall be equal to <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20160202__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember_zFsApj2J3b6g">3,750,000 shares; provided that the maximum number of shares of stock that may be issued under the Plan pursuant to awards shall automatically and without any further Company or shareholder approval, increase on January 1 of each year for not more than 10 years from the effective date, so the number of shares that may be issued is an amount no greater than 20% of the Company’s outstanding shares of stock and shares of stock underlying any outstanding exchangeable shares as of such January 1; provided further that no such increase shall be effective if it would violate any applicable law or stock exchange rule or regulation, or result in adverse tax consequences to the Company or any participant that would not otherwise result but for the increase. Based on the 2016 Option Plan, the Company is authorized to issue employee options with a <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220401__20221231__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember__srt--TitleOfIndividualAxis__custom--EmployeeMember_zUHG0yc6lD6l">10-year term. On March 31, 2020, the Company’s Board of Directors approved the amendment of certain prior options grants, issued to current employees, previously issued with a <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190401__20200331__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember__srt--TitleOfIndividualAxis__custom--EmployeeMember_z1ex1i1QiwJe">3-year term, such that the respective options issued under these agreements would have their term extended to <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190401__20200331__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember_zFwi6OU9uEI6">10 years. The Company revalued these options using a lattice model with an expected life of <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190401__20200331__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorMember_zPJfKNRJGX9j">10 years, risk free rates of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20190401__20200331__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember__srt--RangeAxis__srt--MinimumMember_zYO4gj9g7oMa">0.46% to <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20190401__20200331__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zcmyFUL7igic">0.75%, stock price of $0.974 and expected volatility of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20190401__20200331__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember_zyiZY7ePY3u">132.2%, in order to recognize the additional expense associated with the longer term and recognized a one-time charge of $1,600,515 in share-based compensation, with a corresponding adjustment to adjusted paid in capital. During the three months ended June 30, 2022, the Company granted <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20220401__20220630__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember_zPV4qmTygLej">10,180 of options with a weighted average remaining contractual life of <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220401__20220630__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember_zKppMOEaelb8">10 years. The Company recorded stock-based compensation of $149,190 in connection with ESOP 2016 Plan (June 30, 2021 - $155,851), under general and administrative expenses with corresponding credit to additional paid in capital. During the three months ended September 30, 2022, the Company granted <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20220701__20220930__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember_zoRAqjCtgio2">3,757 of options with a weighted average remaining contractual life of <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220701__20220930__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember_zVFsjDeyb4c3">10 years. The Company recorded stock-based compensation of $153,338 in connection with ESOP 2016 Plan (September 30, 2021 - $169,778), under general and administrative expenses with corresponding credit to additional paid in capital. During the three months ended December 31, 2022, the Company granted no new options. The Company recorded stock-based compensation of $63,125 in connection with ESOP 2016 Plan (December 31, 2021 - $100,650), under general and administrative expenses with corresponding credit to additional paid in capital. BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022 (Unaudited) (Expressed in US dollars) The following table summarizes the stock option activities of the Company to December 31, 2022: SCHEDULE OF STOCK OPTION ACTIVITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of options</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average exercise price ($)</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; width: 60%">Outstanding as of March 31, 2022</td><td style="font-weight: bold; width: 2%"> </td> <td style="font-weight: bold; text-align: left; width: 1%"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220401__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zqezH9mrgwB5" style="font-weight: bold; text-align: right; width: 16%" title="Number of options, beginning outstanding">7,409,714</td><td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; width: 2%"> </td> <td style="font-weight: bold; text-align: left; width: 1%"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220401__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zLrrrLdjpuxd" style="font-weight: bold; text-align: right; width: 16%" title="Weighted average exercise price, beginning outstanding">2.3466</td><td style="font-weight: bold; text-align: left; width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220401__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zlJOWlOiJxHj" style="text-align: right" title="Number of options, granted">10,180</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220401__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zxrt9JYuagc8" style="text-align: right" title="Weighted average exercise price, granted">1.7700</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20220401__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zqztiju3ciLh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options, exercised">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220401__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zpL9sCdTVKof" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, exercised">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Outstanding as of June 30, 2022</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220701__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zWHF0FpP2qb8" style="font-weight: bold; text-align: right" title="Number of options, beginning outstanding">7,419,894</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220701__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zlIBYiPhu7Ke" style="font-weight: bold; text-align: right" title="Weighted average exercise price, beginning outstanding">2.3458</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Granted</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220701__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zsKz63AkZoF3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options, granted">3,757</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220701__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zU9dUVOVEC7c" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, granted">2.2700</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Outstanding as of September 30, 2022</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20221001__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zSmkJRXq8MC6" style="font-weight: bold; text-align: right" title="Number of options, beginning outstanding">7,423,651</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20221001__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zZac14kagUF4" style="font-weight: bold; text-align: right" title="Weighted average exercise price, beginning outstanding">2.3457</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20221001__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zwG8YZuT11Qi" style="text-align: right" title="Number of options, granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20221001__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zMQsYR1nYlU2" style="text-align: right" title="Weighted average exercise price, granted">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20221001__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zq9D0gVS8Jb7" style="text-align: right" title="Number of options, expired">(16,733</td><td style="text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20221001__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zfZIssRmbpjh" style="text-align: right" title="Weighted average exercise price, expired">1.3671</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20221001__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zcGjmaGHf9p2" style="text-align: right" title="Number of options, forfeited">(88,084</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20221001__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zsb5x36G2zgh" style="text-align: right" title="Weighted average exercise price, forfeited">1,9710</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20221001__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zYj54WTrcpCe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options, exercised">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20221001__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zLIqR1KIGznb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, exercised">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 1.5pt">Outstanding as of December 31, 2022</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20221001__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zKhSiscIzFu" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Number of options, ending outstanding">7,318,834</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20221001__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zulqZXVzPOX" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Weighted average exercise price, ending outstanding">2.3509</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> </table>

876205

1802316

7211623

9890144

1563980

11792

53827

876205

1856143

5635851

8368199

37134

114583

151717

118282

839071

1859842

5635851

8334764

839071

1859842

5635851

8334764

278000

306604

218785

531285

839071

1800627

5329247

7968945

839071

1800627

5329247

7968945

1.06

6.26

0.45

3.15

1.06

1.50

August 2026 to January 2031

January 2023 to December 2032

January 2024 to February 2024

3750000

P10Y

P3Y

P10Y

0.0046

0.0075

0.974

1.322

1600515

10180

P10Y

149190

155851

3757

P10Y

153338

169778

63125

100650

The following table summarizes the stock option activities of the Company to December 31, 2022: SCHEDULE OF STOCK OPTION ACTIVITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of options</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average exercise price ($)</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; width: 60%">Outstanding as of March 31, 2022</td><td style="font-weight: bold; width: 2%"> </td> <td style="font-weight: bold; text-align: left; width: 1%"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220401__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zqezH9mrgwB5" style="font-weight: bold; text-align: right; width: 16%" title="Number of options, beginning outstanding">7,409,714</td><td style="font-weight: bold; text-align: left; width: 1%"> </td><td style="font-weight: bold; width: 2%"> </td> <td style="font-weight: bold; text-align: left; width: 1%"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220401__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zLrrrLdjpuxd" style="font-weight: bold; text-align: right; width: 16%" title="Weighted average exercise price, beginning outstanding">2.3466</td><td style="font-weight: bold; text-align: left; width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220401__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zlJOWlOiJxHj" style="text-align: right" title="Number of options, granted">10,180</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220401__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zxrt9JYuagc8" style="text-align: right" title="Weighted average exercise price, granted">1.7700</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20220401__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zqztiju3ciLh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options, exercised">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220401__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zpL9sCdTVKof" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, exercised">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Outstanding as of June 30, 2022</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220701__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zWHF0FpP2qb8" style="font-weight: bold; text-align: right" title="Number of options, beginning outstanding">7,419,894</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220701__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zlIBYiPhu7Ke" style="font-weight: bold; text-align: right" title="Weighted average exercise price, beginning outstanding">2.3458</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Granted</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220701__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zsKz63AkZoF3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options, granted">3,757</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220701__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zU9dUVOVEC7c" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, granted">2.2700</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Outstanding as of September 30, 2022</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20221001__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zSmkJRXq8MC6" style="font-weight: bold; text-align: right" title="Number of options, beginning outstanding">7,423,651</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20221001__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zZac14kagUF4" style="font-weight: bold; text-align: right" title="Weighted average exercise price, beginning outstanding">2.3457</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20221001__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zwG8YZuT11Qi" style="text-align: right" title="Number of options, granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20221001__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zMQsYR1nYlU2" style="text-align: right" title="Weighted average exercise price, granted">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20221001__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zq9D0gVS8Jb7" style="text-align: right" title="Number of options, expired">(16,733</td><td style="text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20221001__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zfZIssRmbpjh" style="text-align: right" title="Weighted average exercise price, expired">1.3671</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20221001__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zcGjmaGHf9p2" style="text-align: right" title="Number of options, forfeited">(88,084</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20221001__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zsb5x36G2zgh" style="text-align: right" title="Weighted average exercise price, forfeited">1,9710</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20221001__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zYj54WTrcpCe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options, exercised">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20221001__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zLIqR1KIGznb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, exercised">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 1.5pt">Outstanding as of December 31, 2022</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20221001__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zKhSiscIzFu" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Number of options, ending outstanding">7,318,834</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20221001__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zulqZXVzPOX" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Weighted average exercise price, ending outstanding">2.3509</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> </table>

7409714

2.3466

10180

1.7700

7419894

2.3458

3757

2.2700

7423651

2.3457

16733

1.3671

88084

1.9710

7318834

2.3509

<p id="xdx_899_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zP1KYP66RH8c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The fair value of each option granted is estimated at the time of grant using the Black Scholes model using the following assumptions, for each of the respective fiscal year: SCHEDULE OF FAIR VALUE OF OPTION GRANTED USING VALUATION ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Fiscal Year 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Fiscal Year 2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> </tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">Exercise price ($)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20230331__srt--StatementScenarioAxis__srt--ScenarioForecastMember__srt--RangeAxis__srt--MinimumMember_zr9ItDiHqdg5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.77 – <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20230331__srt--StatementScenarioAxis__srt--ScenarioForecastMember__srt--RangeAxis__srt--MaximumMember_z9DsUjf5HOOh">2.27</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220331__srt--RangeAxis__srt--MinimumMember_z85DLAJoZZ5f" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.40 – 3.98</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td> </tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk free interest rate (%)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220401__20230331__srt--StatementScenarioAxis__srt--ScenarioForecastMember__srt--RangeAxis__srt--MinimumMember_zYmnT6Mw8XSi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.00 – <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220401__20230331__srt--StatementScenarioAxis__srt--ScenarioForecastMember__srt--RangeAxis__srt--MaximumMember_zkReIlZOynul">4.06</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20210401__20220331__srt--RangeAxis__srt--MinimumMember_z6OnFXgvMRih" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.34 – <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20210401__20220331__srt--RangeAxis__srt--MaximumMember_zhHyh2LXFlAi">2.32</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> </tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected term (Years)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220401__20230331__srt--StatementScenarioAxis__srt--ScenarioForecastMember__srt--RangeAxis__srt--MinimumMember_zIxxvY2P2sM2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 – <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220401__20230331__srt--StatementScenarioAxis__srt--ScenarioForecastMember__srt--RangeAxis__srt--MaximumMember_zyRVdyAyB1F2">6.5</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210401__20220331__srt--RangeAxis__srt--MinimumMember_zlBWcmUPmX53" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.0 – 10.0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> </tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected volatility (%)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20220401__20230331__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zO8CCsMqRtA9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">107.7 – 119.5</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20210401__20220331__srt--RangeAxis__srt--MinimumMember_z5GUUzO0J8L7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">106.6 – <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20210401__20220331__srt--RangeAxis__srt--MaximumMember_z5Is9GtK2yQ6">129.9</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> </tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected dividend yield (%)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220401__20230331__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zPfaozdmc884" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Expected dividend yield">0.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210401__20220331_z7TZrlbpNKNi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Expected dividend yield">0.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> </tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Fair value of option ($)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20230331__srt--StatementScenarioAxis__srt--ScenarioForecastMember__srt--RangeAxis__srt--MinimumMember_zyzjtL0sngNk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.36 – <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20230331__srt--StatementScenarioAxis__srt--ScenarioForecastMember__srt--RangeAxis__srt--MaximumMember_z1cL0HPu3K8d">1.57</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20220331__srt--RangeAxis__srt--MinimumMember_znTOerpoJEYb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.19 – 3.52</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> </tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected forfeiture (attrition) rate (%)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_ecustom--ExpectedForfeitureAttritionRates_pid_dp_uPure_c20220401__20230331__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zmuGMPClhvG5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Expected forfeiture (attrition) rate">0.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_ecustom--ExpectedForfeitureAttritionRates_pid_dp_uPure_c20210401__20220331_zvg7M8lBowze" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Expected forfeiture (attrition) rate">0.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> </tr> </table>

1.77

2.27

2.40

3.98

0.0300

0.0406

0.0034

0.0232

P5Y

P6Y6M

P2Y

P10Y

1.077

1.066

1.299

0.0000

0.36

1.57

1.19

3.52

0.0000 0.0000

10. OPERATING LEASE RIGHT-OF-USE ASSETS AND LEASE LIABILITIES The Company has one operating lease primarily for office and administration. During December 2021, the Company entered into a new lease agreement. The Company paid $85,000 deposit that would be returned at the end of the lease. In December 2022, the Company started a new lease with an additional suite in the same premise as the existing lease. When measuring the lease obligations, the Company discounted lease payments using its incremental borrowing rate. The weighted-average-rate applied is 11.4%. SCHEDULE OF OPERATING LEASES OBLIGATIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-weight: bold">Right of Use Asset</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">$</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%">Balance at March 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--OperatingLeaseRightOfUseAsset_iS_c20220401__20221231_zFxc0rm9ladj" style="width: 18%; text-align: right" title="Operating lease right-of-use asset, beginning balance">1,242,700</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">New leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">685,099</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_iN_di_c20220401__20221231_zqC1eb1Xip3f" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization">(255,146</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance at December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--OperatingLeaseRightOfUseAsset_iE_c20220401__20221231_zwJRPzGnshwa" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease right-of-use asset, ending balance">1,672,653</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">Lease Liability</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">$</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%">Balance at March 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--OperatingLeaseLiability_iS_c20220401__20221231_zTr5nwxzXCS9" style="width: 18%; text-align: right" title="Operating lease liability, beginning balance">1,330,338</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">New leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">685,099</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Repayment and interest accretion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_ecustom--OperatingLeaseRepaymentAndInterestAccretion_iN_di_c20220401__20221231_zgxlplTxG6aj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Repayment and interest accretion">(231,533</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance at December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--OperatingLeaseLiability_iE_c20220401__20221231_zol6yWzUO9N9" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease liability, ending balance">1,783,904</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Current portion of operating lease liability</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20221231_z7qdM1P7soWk" style="text-align: right" title="Current portion of operating lease liability">322,882</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Noncurrent portion of operating lease liability</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20221231_zQOrgwDISK97" style="text-align: right" title="Noncurrent portion of operating lease liability">1,461,022</td><td style="text-align: left"> </td></tr> </table> The operating lease expense was $53,286 and $264,738 for the three and nine months ended December 31, 2022, respectively. (December 31, 2021: $119,465 and $255,020) was included in the general and administrative expenses. <p id="xdx_89B_ecustom--ScheduleOfContractualUndiscountedCashFlowsForLeaseObligationTableTextBlock_zQt1rosvrIcl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table represents the contractual undiscounted cash flows for lease obligations as at December 31, 2022: SCHEDULE OF CONTRACTUAL UNDISCOUNTED CASH FLOWS FOR LEASE OBLIGATION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20221231_zsluWexNGVyf" style="border-bottom: Black 1.5pt solid; text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-weight: bold">Calendar year</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">$</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_zzKf27IPJgl3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">505,696</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_ztx7t856ENh6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">552,293</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_zvyhotZp5k5a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">600,288</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_zV9Q7XlRouAj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">565,359</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndAfter_iI_z0ER1R3dgH17" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">2027 and beyond</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_zr3E1oy2lti5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total undiscounted lease liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,223,636</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--LesseeOperatingLeaseLiabilityLessImputedInterest_iI_z1TwQOPo9iEa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(439,732</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_zCCkc9dAstof" style="vertical-align: bottom; background-color: White"> <td>Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,783,904 </td><td style="text-align: left"> </td></tr> </table>

85000

0.114

SCHEDULE OF OPERATING LEASES OBLIGATIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-weight: bold">Right of Use Asset</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">$</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%">Balance at March 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--OperatingLeaseRightOfUseAsset_iS_c20220401__20221231_zFxc0rm9ladj" style="width: 18%; text-align: right" title="Operating lease right-of-use asset, beginning balance">1,242,700</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">New leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">685,099</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_iN_di_c20220401__20221231_zqC1eb1Xip3f" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization">(255,146</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance at December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--OperatingLeaseRightOfUseAsset_iE_c20220401__20221231_zwJRPzGnshwa" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease right-of-use asset, ending balance">1,672,653</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">Lease Liability</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">$</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%">Balance at March 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--OperatingLeaseLiability_iS_c20220401__20221231_zTr5nwxzXCS9" style="width: 18%; text-align: right" title="Operating lease liability, beginning balance">1,330,338</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">New leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">685,099</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Repayment and interest accretion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_ecustom--OperatingLeaseRepaymentAndInterestAccretion_iN_di_c20220401__20221231_zgxlplTxG6aj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Repayment and interest accretion">(231,533</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance at December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--OperatingLeaseLiability_iE_c20220401__20221231_zol6yWzUO9N9" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease liability, ending balance">1,783,904</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Current portion of operating lease liability</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20221231_z7qdM1P7soWk" style="text-align: right" title="Current portion of operating lease liability">322,882</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Noncurrent portion of operating lease liability</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20221231_zQOrgwDISK97" style="text-align: right" title="Noncurrent portion of operating lease liability">1,461,022</td><td style="text-align: left"> </td></tr> </table>

1242700

685099

255146

1672653

1330338

685099 231533

1783904

322882

1461022

53286

264738

119465

255020

<p id="xdx_89B_ecustom--ScheduleOfContractualUndiscountedCashFlowsForLeaseObligationTableTextBlock_zQt1rosvrIcl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table represents the contractual undiscounted cash flows for lease obligations as at December 31, 2022: SCHEDULE OF CONTRACTUAL UNDISCOUNTED CASH FLOWS FOR LEASE OBLIGATION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20221231_zsluWexNGVyf" style="border-bottom: Black 1.5pt solid; text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-weight: bold">Calendar year</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">$</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_zzKf27IPJgl3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">505,696</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_ztx7t856ENh6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">552,293</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_zvyhotZp5k5a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">600,288</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_zV9Q7XlRouAj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">565,359</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndAfter_iI_z0ER1R3dgH17" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">2027 and beyond</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_zr3E1oy2lti5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total undiscounted lease liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,223,636</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--LesseeOperatingLeaseLiabilityLessImputedInterest_iI_z1TwQOPo9iEa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(439,732</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_zCCkc9dAstof" style="vertical-align: bottom; background-color: White"> <td>Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,783,904 </td><td style="text-align: left"> </td></tr> </table>

505696

552293

600288

565359

2223636

-439732

1783904

11. PROPERTY AND EQUIPMENT During the year-ended March 31, 2022, the Company purchased leasehold improvements of $12,928 (useful life: 5 years) as well as furniture & fixtures of $16,839 (useful life: 5 years). The Company recognized depreciation expense for these assets in the amount of $1,487 and $4,465 during the three and nine months ended December 31, 2022 (December 31, 2021: $819, $819): SCHEDULE OF PROPERTY AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Cost</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Office equipment</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Leasehold improvement</td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Balance at March 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iS_c20220401__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zyOZbs3BVA1a" style="width: 14%; text-align: right" title="Cost, beginning balance">16,839</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iS_c20220401__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zxK9VEREPsQ6" style="width: 14%; text-align: right" title="Cost, beginning balance">12,928</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iS_c20220401__20221231_zK1pUCOARvok" style="width: 14%; text-align: right" title="Cost, beginning balance">29,767</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Additions</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentAdditions_c20220401__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zx6K4Y6L7rI" style="border-bottom: Black 1.5pt solid; text-align: right" title="Additions">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentAdditions_c20220401__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zyZDVi9pMX9h" style="border-bottom: Black 1.5pt solid; text-align: right" title="Additions">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentAdditions_c20220401__20221231_zXUxYq9ESiI" style="border-bottom: Black 1.5pt solid; text-align: right" title="Additions">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 1.5pt">Balance at December 31, 2022</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iE_c20220401__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zbiO2438STph" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Cost, ending balance">16,839</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iE_c20220401__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zRcqFIjso94b" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Cost, ending balance">12,928</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iE_c20220401__20221231_z895Zjo6Xxv7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Cost, ending balance">29,767</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> </table> BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022 (Unaudited) (Expressed in US dollars) <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Accumulated depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Office equipment</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Leasehold improvement</td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Balance at March 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iS_c20220401__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zBofRXLzhmhk" style="width: 14%; text-align: right" title="Accumulated depreciation, beginning balance">1,308</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iS_c20220401__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z1NHBcONILMk" style="width: 14%; text-align: right" title="Accumulated depreciation, beginning balance">1,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iS_c20220401__20221231_zikHrktHVkWf" style="width: 14%; text-align: right" title="Accumulated depreciation, beginning balance">2,308</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Depreciation for Q1</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--Depreciation_c20220401__20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zdmZVzPMLg74" style="text-align: right" title="Depreciation">842</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--Depreciation_c20220401__20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zVfgSw9a0zd7" style="text-align: right" title="Depreciation">647</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--Depreciation_c20220401__20220630_zSzO8Yy5njS8" style="text-align: right" title="Depreciation">1,489</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Depreciation for Q2</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--Depreciation_c20220701__20220930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zwAcKIV1LVG9" style="text-align: right" title="Depreciation">842</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--Depreciation_c20220701__20220930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zglrmGQap35h" style="text-align: right" title="Depreciation">647</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--Depreciation_c20220701__20220930_z6ORC6ZCyf0k" style="text-align: right" title="Depreciation">1,489</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Depreciation for Q3</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p id="xdx_98C_eus-gaap--Depreciation_c20221001__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zRu4YeK9gST7" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Depreciation">841</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p id="xdx_98D_eus-gaap--Depreciation_c20221001__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zMFRiszmVqi4" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Depreciation">646</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--Depreciation_c20221001__20221231_zw21xuRynzdi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Depreciation">1,487</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 1.5pt">Balance at December 31, 2022</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_98F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iE_c20220401__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_z5O0h8yfvV8i" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Accumulated depreciation, ending balance">3,833 </td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_98E_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iE_c20220401__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_ziGSeGNrPcX7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Accumulated depreciation, ending balance">2,940</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_987_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iE_c20220401__20221231_z71zAelsTmTi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Accumulated depreciation, ending balance">6,773</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Net book value</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Balance at March 31, 2022</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentNet_iS_c20220401__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zJouum3otFGk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net book value, beginning balance">15,531</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentNet_iS_c20220401__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zPXx4lTToJlj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net book value, beginning balance">11,928</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentNet_iS_c20220401__20221231_zeASNR9rrYy5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net book value, beginning balance">27,459</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 1.5pt">Balance at December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p id="xdx_984_eus-gaap--PropertyPlantAndEquipmentNet_iE_c20220401__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zNRdaBSThtd4" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Net book value, ending balance">13,006</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p id="xdx_987_eus-gaap--PropertyPlantAndEquipmentNet_iE_c20220401__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zMDYvNJ9ajp3" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Net book value, ending balance">9,988 </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentNet_iE_c20220401__20221231_ztC2XpIc3KD1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Net book value, ending balance">22,994</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> </table>

12928

P5Y

16839

P5Y

1487

4465

819

SCHEDULE OF PROPERTY AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Cost</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Office equipment</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Leasehold improvement</td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Balance at March 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iS_c20220401__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zyOZbs3BVA1a" style="width: 14%; text-align: right" title="Cost, beginning balance">16,839</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iS_c20220401__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zxK9VEREPsQ6" style="width: 14%; text-align: right" title="Cost, beginning balance">12,928</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iS_c20220401__20221231_zK1pUCOARvok" style="width: 14%; text-align: right" title="Cost, beginning balance">29,767</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Additions</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentAdditions_c20220401__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zx6K4Y6L7rI" style="border-bottom: Black 1.5pt solid; text-align: right" title="Additions">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentAdditions_c20220401__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zyZDVi9pMX9h" style="border-bottom: Black 1.5pt solid; text-align: right" title="Additions">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentAdditions_c20220401__20221231_zXUxYq9ESiI" style="border-bottom: Black 1.5pt solid; text-align: right" title="Additions">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 1.5pt">Balance at December 31, 2022</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iE_c20220401__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zbiO2438STph" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Cost, ending balance">16,839</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iE_c20220401__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zRcqFIjso94b" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Cost, ending balance">12,928</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iE_c20220401__20221231_z895Zjo6Xxv7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Cost, ending balance">29,767</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> </table> BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022 (Unaudited) (Expressed in US dollars) <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Accumulated depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Office equipment</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Leasehold improvement</td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Balance at March 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iS_c20220401__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zBofRXLzhmhk" style="width: 14%; text-align: right" title="Accumulated depreciation, beginning balance">1,308</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iS_c20220401__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z1NHBcONILMk" style="width: 14%; text-align: right" title="Accumulated depreciation, beginning balance">1,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iS_c20220401__20221231_zikHrktHVkWf" style="width: 14%; text-align: right" title="Accumulated depreciation, beginning balance">2,308</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Depreciation for Q1</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--Depreciation_c20220401__20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zdmZVzPMLg74" style="text-align: right" title="Depreciation">842</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--Depreciation_c20220401__20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zVfgSw9a0zd7" style="text-align: right" title="Depreciation">647</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--Depreciation_c20220401__20220630_zSzO8Yy5njS8" style="text-align: right" title="Depreciation">1,489</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Depreciation for Q2</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--Depreciation_c20220701__20220930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zwAcKIV1LVG9" style="text-align: right" title="Depreciation">842</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--Depreciation_c20220701__20220930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zglrmGQap35h" style="text-align: right" title="Depreciation">647</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--Depreciation_c20220701__20220930_z6ORC6ZCyf0k" style="text-align: right" title="Depreciation">1,489</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Depreciation for Q3</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p id="xdx_98C_eus-gaap--Depreciation_c20221001__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zRu4YeK9gST7" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Depreciation">841</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p id="xdx_98D_eus-gaap--Depreciation_c20221001__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zMFRiszmVqi4" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Depreciation">646</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--Depreciation_c20221001__20221231_zw21xuRynzdi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Depreciation">1,487</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 1.5pt">Balance at December 31, 2022</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_98F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iE_c20220401__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_z5O0h8yfvV8i" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Accumulated depreciation, ending balance">3,833 </td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_98E_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iE_c20220401__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_ziGSeGNrPcX7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Accumulated depreciation, ending balance">2,940</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_987_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iE_c20220401__20221231_z71zAelsTmTi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Accumulated depreciation, ending balance">6,773</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Net book value</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Balance at March 31, 2022</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentNet_iS_c20220401__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zJouum3otFGk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net book value, beginning balance">15,531</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentNet_iS_c20220401__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zPXx4lTToJlj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net book value, beginning balance">11,928</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentNet_iS_c20220401__20221231_zeASNR9rrYy5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net book value, beginning balance">27,459</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 1.5pt">Balance at December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p id="xdx_984_eus-gaap--PropertyPlantAndEquipmentNet_iE_c20220401__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zNRdaBSThtd4" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Net book value, ending balance">13,006</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p id="xdx_987_eus-gaap--PropertyPlantAndEquipmentNet_iE_c20220401__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zMDYvNJ9ajp3" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Net book value, ending balance">9,988 </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentNet_iE_c20220401__20221231_ztC2XpIc3KD1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Net book value, ending balance">22,994</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> </table>

16839

12928

29767

16839

12928

29767

1308

1000

2308

842

647

1489

842

647

1489

841

646

1487

3833

2940

6773

15531

11928

27459

13006

9988

22994

12. CONTINGENCIES There are no unrecognized claims against the Company that were assessed as significant, which were outstanding as at December 31, 2022 and, consequently, no additional provision for such has been recognized in the condensed consolidated financial statements during the three and nine months then ended.

13. SUBSEQUENT EVENTS The Company’s management has evaluated subsequent events up to February 14, 2023, the date the condensed consolidated financial statements were issued, pursuant to the requirements of ASC 855, and has determined the following material subsequent events: On January 23, 2023, the Company issued a new convertible note to an individual in the amount of $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20230131__us-gaap--DebtInstrumentAxis__custom--NewConvertibleNoteMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zk7Z7Ll71uA7">2,000,000 (“principal amount”). This note bears interest with a fixed rate of <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20230131__us-gaap--DebtInstrumentAxis__custom--NewConvertibleNoteMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zPxj29d4smrg">10% for its entire 18-month term, paid in advance through the issuance of common stock. On January 23, the company issued <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230131__20230131__us-gaap--DebtInstrumentAxis__custom--NewConvertibleNoteMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zvq5LQv3GuX4">270,270 shares to this individual in payment of this interest, using a share price of $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20230131__us-gaap--DebtInstrumentAxis__custom--NewConvertibleNoteMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zhLScz3y3b7k">0.74 per share, which is a strike price equal to the lowest Company stock price on the note issuance date. The note maybe repaid in cash, or via conversion of note principal, subject to mutual consent of the Company and the note holder, at <span id="xdx_90B_eus-gaap--DebtInstrumentRedemptionPricePercentage_pid_dp_uPure_c20230101__20230131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--DebtConvertibleNoteHolderMember_zSBVtxWp7Ku5">15% discount to the stock’s VWAP on the conversion date. In addition, the note holder has the option to convert, after a qualified financing through the earlier of the prepayment date or maturity date, all of the outstanding principal and accrued interest thereon, based upon a conversion price equal to a 20% discount to the lessor of (i) the actual price per new round of stock based on qualified financing, (ii) if there be no qualified financing as of the maturity date, by mutual consent and election of the Company and the note holder, at <span id="xdx_90C_eus-gaap--DebtInstrumentRedemptionPricePercentage_dp_uPure_c20230101__20230131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--DebtConvertibleNoteHolderMember_zoFJZwxQFEje">15% discount to average VWAP for ten consecutive trading days immediately prior to the maturity date.

2000000

0.10

270270

0.74

0.15

0.20

0.15